var title_f40_16_41216="Indeterminate thyroid nodule scan I";
var content_f40_16_41216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Indeterminate thyroid nodule: Appearance on thyroid scintigraphy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    123-I thyroid scan of a 2 cm papillary cancer, which does not appear as a nonfunctioning nodule because it overlies normal isotope concentration in the uninvolved portion of the right lobe.",
"    <div class=\"footnotes\">",
"     SSN: suprasternal notch.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41216=[""].join("\n");
var outline_f40_16_41216=null;
var title_f40_16_41217="Skin biopsy incision technique";
var content_f40_16_41217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin biopsy incision parallel to wrinkle lines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin tension lines (Langer's lines) can be revealed by compressing the skin. A diamond-shaped or elliptical excision is outlined with its long axis parallel to the wrinkle lines. Incisions performed parallel to tension lines will close more easily and with a better cosmetic result than those performed at right angles to the tension lines.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41217=[""].join("\n");
var outline_f40_16_41217=null;
var title_f40_16_41218="Scabies distribution PI";
var content_f40_16_41218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parts of the body affected by scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 551px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scabies usually affects the sides and webs of the fingers, inside of the wrists, elbows, armpits, skin around the nipples (especially in women), skin around the belly button, waist, male genitals (scrotum and penis), knees, lower half of the butt and tops of thighs, and sides and backs of the feet. The back is not usually affected. The head is not usually affected except in very young children.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41218=[""].join("\n");
var outline_f40_16_41218=null;
var title_f40_16_41219="Conjunctivitis and uveitis";
var content_f40_16_41219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Conjunctivitis and anterior uveitis in reactive arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Conjunctival injection and anterior uveitis (iritis) with hypopyon are noted in the photograph of the eye of a patient with reactive arthritis (formerly Reiter's Syndrome).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Filip de Keyser.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41219=[""].join("\n");
var outline_f40_16_41219=null;
var title_f40_16_41220="Normal sexual differentiation";
var content_f40_16_41220=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Normal sexual differentiation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/16/41220/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41220/contributors\">",
"     James E Griffin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41220/contributors\">",
"     Jean D Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/16/41220/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41220/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41220/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/16/41220/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41220/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/16/41220/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal sexual development during embryogenesis consists of three related sequential processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establishment of chromosomal (genetic) sex at fertilization, with XY as male and XX as female. For the first two months of human gestation the two sexes develop in an identical fashion.",
"     </li>",
"     <li>",
"      Determination of gonadal sex when the indifferent gonad develops into an ovary or a testis, beginning around week eight and subsequent secretion of hormones by the fetal testes.",
"     </li>",
"     <li>",
"      Development of sexual phenotypes when the sexually indifferent anlagen of the urogenital tract develop into characteristic male or female structures. This process is largely completed by week 12 in the male and somewhat later in the female.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the major steps in normal sexual differentiation. The hormonal regulation of testosterone production and the role of androgens and gonadotropins in spermatogenesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31800?source=see_link\">",
"     \"Male reproductive physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMIC ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenotypic differentiation of the female and male urogenital tracts are as follows (",
"    <a class=\"graphic graphic_figure graphicRef78289 \" href=\"mobipreview.htm?2/10/2214\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Internal urogenital tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal urogenital tracts arise from sexually indifferent gonads and two sets of ducts, the wolffian and m&uuml;llerian ducts that are present in early embryos of both sexes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In females the gonads become ovaries, the m&uuml;llerian ducts give rise to the fallopian tubes, uterus, and upper vagina, and the wolffian ducts persist in vestigial form.",
"     </li>",
"     <li>",
"      In males the gonads become testes, the wolffian ducts give rise to the epididymides, vasa deferentia, seminal vesicles, and ejaculatory ducts, and the m&uuml;llerian ducts regress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     External genitalia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The external genitalia in the two sexes develop from common anlagen: the genital tubercle, the genital swellings, and the genital folds (",
"    <a class=\"graphic graphic_figure graphicRef65480 \" href=\"mobipreview.htm?31/56/32645\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In females the genital tubercle becomes the clitoris, the genital swellings become the labia majora, and the genital folds become the labia minora.",
"     </li>",
"     <li>",
"      In males the genital swellings fuse to become the scrotum, the genital folds elongate and fuse to form the shaft of the penis and the penile urethra which terminates in the glans penis formed from the genital tubercle. Prostatic buds develop in the wall of the proximal urethra and elongate and arborize to form the prostate. Testicular descent takes place in the latter part of gestation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     THE JOST MODEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the model formulated by the physiologist Alfred Jost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/1\">",
"     1",
"    </a>",
"    ], chromosomal (genetic) sex determines gonadal sex, and gonadal sex, in turn, determines phenotypic sex. If a testis develops, the urogenital tract becomes male in character, and if an ovary (or no gonad) is present the urogenital tract is female in character.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GONADAL DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of genes have been identified that are essential for development of both ovaries and testes. These genes include Emx2,",
"    <span class=\"nowrap\">",
"     Igf1r/Irr/Ir,",
"    </span>",
"    Lhx9, M33, Sf1, and Wt1; homozygous deletion of these genes in mice causes failure of development or early regression of the gonads in both sexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TESTICULAR DETERMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The critical region of the Y chromosome that causes development of the testes is now established. SRY (sex determining region of the Y chromosome) causes the indifferent gonad to develop into a testis, and insertion of this single gene as a transgene into female animals is sufficient to cause development of a testis and mature male phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/4\">",
"     4",
"    </a>",
"    ]. Evidence suggests that the fundamental effect of SRY to stimulate testis development is to suppress ovarian development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/5\">",
"     5",
"    </a>",
"    ]. SRY is also believed to activate a series of additional so-called downstream genes to promote development of the Leydig cells, Sertoli cells, and the spermatogenic tubules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Particularly strong evidence exists for the importance of the following downstream genes: Sox9, Sox8, Fgf9, Dmrt1, and Dax1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DEVELOPMENT OF THE MALE PHENOTYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadal sex is translated into male phenotypic sex by hormonal secretions of the fetal testes. Three hormones are responsible for development of the male phenotype: anti-m&uuml;llerian hormone (AMH) (also called m&uuml;llerian-inhibiting hormone [MIH] and m&uuml;llerian-inhibiting substance [MIS]), testosterone, and dihydrotestosterone. The net effect of these hormones is regression of the m&uuml;llerian ducts and promotion of development of the male urogenital tract and external genitalia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-m&uuml;llerian hormone, a glycoprotein formed by Sertoli cells of the fetal testis beginning at about six weeks of development, causes regression of the m&uuml;llerian ducts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Testosterone, secreted by the fetal testes beginning at about the eighth week of development, directly stimulates Wolffian duct differentiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dihydrotestosterone formed by 5-alpha-reduction of testosterone causes development of the male external genitalia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/9\">",
"       9",
"      </a>",
"      ]. The importance of dihydrotestosterone formation for normal male sexual differentiation was suggested by studies of testosterone metabolism in embryonic tissues [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/9\">",
"       9",
"      </a>",
"      ] and proven by the observation that an autosomal recessive mutation, steroid 5-alpha-reductase 2 deficiency, impairs development of the male external genitalia in humans. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30423?source=see_link\">",
"       \"Steroid 5-alpha-reductase 2 deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     5-alpha-reduction of testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone is the principal androgen secreted by fetal and adult testes. It can be metabolized to two types of active metabolites, 5-alpha-reduced androgens and estrogens. Dihydrotestosterone is the most important 5-alpha-reduced androgen and serves as the intracellular mediator of many androgen actions. Its serum concentrations are about one-tenth those of testosterone, and the circulating hormone originates primarily from extraglandular formation. Two steroid 5-alpha-reductases convert testosterone to dihydrotestosterone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/10\">",
"     10",
"    </a>",
"    ]. Isoenzyme 2 is the primary enzyme in androgen target tissues of the male reproductive tract and is inhibited by 5-alpha-reductase inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31800?source=see_link\">",
"     \"Male reproductive physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Estrogen formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In males, the potent estrogen estradiol is principally formed in extraglandular tissues, either directly by the aromatization of testosterone or indirectly by the sequential conversion of androstenedione to estrone and estrone to estradiol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct secretion of estradiol by the testis normally accounts for only about 15 percent of the 50 mcg of estradiol formed each day in normal men. Testicular secretion of estradiol increases when serum luteinizing hormone (LH) concentrations are high. In men, estradiol may be essential for normal bone maturation and metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], and excess estrogen causes feminization (gynecomastia). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/9/6294?source=see_link\">",
"     \"Epidemiology and pathogenesis of gynecomastia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Androgen action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone and dihydrotestosterone bind to the same intracellular receptor, a member of the steroid-thyroid-retinoid superfamily of transcription regulatory factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/14\">",
"     14",
"    </a>",
"    ]. The androgen receptor contains DNA-binding and hormone-binding domains in the C-terminal portion of the protein and a region in the N-terminal region important for transactivation of the target gene. At least in regard to the external genitalia, androgen activates expression of local growth factors involving the",
"    <span class=\"nowrap\">",
"     Wnt/beta-catenin",
"    </span>",
"    system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to virilization of the wolffian ducts during embryogenesis, the testosterone-receptor complex plays a role in feedback regulation of LH secretion by the pituitary and the androgen-dependent component of spermatogenesis.",
"   </p>",
"   <p>",
"    Dihydrotestosterone formation serves as an amplification mechanism for androgen action. It binds to the receptor with greater affinity and activates reporter genes in vitro more efficiently than testosterone&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/16\">",
"     16",
"    </a>",
"    ]. In postnatal life, the dihydrotestosterone-receptor complex is responsible for most aspects of sexual maturation at the time of male puberty including facial and body hair, temporal hair recession, and maturation of the external genitalia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OVARIAN DETERMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of ovarian development is believed to involve an active genetic pathway, including R spondin 1",
"    <span class=\"nowrap\">",
"     (Rspo1)/Wnt-4/beta-catenin",
"    </span>",
"    signaling that is repressed by the presence of SRY. Evidence for this comes from experimental studies of mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/17-19\">",
"     17-19",
"    </a>",
"    ] and human mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41220/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DEVELOPMENT OF THE FEMALE PHENOTYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal female reproductive tract is formed from the m&uuml;llerian ducts. The cephalic portions of the m&uuml;llerian ducts develop into the fallopian tubes, and the caudal portions of the ducts fuse to form the uterus. At the site of contact of the m&uuml;llerian ducts with the urogenital sinus, a proliferation of endodermal cells forms the uterovaginal plate which eventually canalizes to form the lumen of the vagina. In contrast to the male in which the urogenital sinus is enclosed by fusion of the genital folds, most of the urogenital sinus of the female remains exposed on the surface as a cleft into which the vagina and urethra open. The urogenital tubercle forms the clitoris.",
"   </p>",
"   <p>",
"    In the absence of testes (as in normal females or when both gonads are missing), the development of phenotypic sex is female. Thus, female development is independent of hormones of the fetal ovary. However, embryogenesis takes place in the presence of a multitude of hormones derived from the placenta, the maternal circulation, the fetal adrenal, the fetal testis, and possibly the fetal ovary. Because the embryo develops in the \"female environment\" of the mother, it has not been possible to devise a definitive experiment to determine whether any of these hormones are essential for female development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BREAST DEVELOPMENT IN BOTH SEXES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast buds in embryos develop along the so-called \"mammary lines\" which are epidermal thickenings on the ventral surface. In the human, the lines disappear except for a small portion on each side of the thorax that condenses to penetrate the underlying mesenchyme. This single pair of mammary buds undergoes little change until the fifth month of development when nipples develop. Proliferation of rudimentary ducts during the remainder of gestation results in 15 to 25 separate glands connected to the exterior through the nipple. The development of the breast is identical in both sexes until puberty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual differentiation is a sequential and ordered process in which chromosomal sex determines whether the gonad will develop into an ovary or testis and in which testes secrete hormones that convert the basic female (or default) phenotype into a male urogenital tract and external genitalia. The mechanisms by which the SRY gene on the Y chromosome dictates testicular development and testicular hormones promote male development are incompletely understood.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/1\">",
"      Jost A. Hormonal factors in the sex differentiation of the mammalian foetus. Philos Trans R Soc Lond B Biol Sci 1970; 259:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/2\">",
"      MacLaughlin DT, Donahoe PK. Sex determination and differentiation. N Engl J Med 2004; 350:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/3\">",
"      Brennan J, Capel B. One tissue, two fates: molecular genetic events that underlie testis versus ovary development. Nat Rev Genet 2004; 5:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/4\">",
"      Sinclair AH, Berta P, Palmer MS, et al. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 1990; 346:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/5\">",
"      Lau YF, Li Y. The human and mouse sex-determining SRY genes repress the Rspol/beta-catenin signaling. J Genet Genomics 2009; 36:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/6\">",
"      Meeks JJ, Weiss J, Jameson JL. Dax1 is required for testis determination. Nat Genet 2003; 34:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/7\">",
"      Wilhelm D, Palmer S, Koopman P. Sex determination and gonadal development in mammals. Physiol Rev 2007; 87:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/8\">",
"      Josso N, Boussin L, Knebelmann B, et al. Anti-M&uuml;llerian hormone and intersex states. Trends Endocrinol Metab 1991; 2:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/9\">",
"      Siiteri PK, Wilson JD. Testosterone formation and metabolism during male sexual differentiation in the human embryo. J Clin Endocrinol Metab 1974; 38:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/10\">",
"      Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci U S A 1990; 87:3640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/11\">",
"      MacDonald PC, Madden JD, Brenner PF, et al. Origin of estrogen in normal men and in women with testicular feminization. J Clin Endocrinol Metab 1979; 49:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/12\">",
"      Bulun SE. Clinical review 78: Aromatase deficiency in women and men: would you have predicted the phenotypes? J Clin Endocrinol Metab 1996; 81:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/13\">",
"      Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/14\">",
"      O'Malley B. The steroid receptor superfamily: more excitement predicted for the future. Mol Endocrinol 1990; 4:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/15\">",
"      Miyagawa S, Satoh Y, Haraguchi R, et al. Genetic interactions of the androgen and Wnt/beta-catenin pathways for the masculinization of external genitalia. Mol Endocrinol 2009; 23:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/16\">",
"      Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 1992; 88:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/17\">",
"      Vainio S, Heikkil&auml; M, Kispert A, et al. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999; 397:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/18\">",
"      Sekido, R, Lovell-Badge, R. Sex determination and SRY: down to wink and a nudge? Trends in Genetics 2009; 25: 19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/19\">",
"      Cool J, Capel B. Mixed signals: development of the testis. Semin Reprod Med 2009; 27:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41220/abstract/20\">",
"      Biason-Lauber A, Konrad D, Navratil F, Schoenle EJ. A WNT4 mutation associated with M&uuml;llerian-duct regression and virilization in a 46,XX woman. N Engl J Med 2004; 351:792.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7472 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41220=[""].join("\n");
var outline_f40_16_41220=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMIC ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Internal urogenital tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      External genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      THE JOST MODEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GONADAL DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TESTICULAR DETERMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DEVELOPMENT OF THE MALE PHENOTYPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      5-alpha-reduction of testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Estrogen formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Androgen action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OVARIAN DETERMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DEVELOPMENT OF THE FEMALE PHENOTYPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BREAST DEVELOPMENT IN BOTH SEXES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7472\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7472|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/10/2214\" title=\"figure 1\">",
"      Development internal genitalia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/56/32645\" title=\"figure 2\">",
"      Development external genitalia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/9/6294?source=related_link\">",
"      Epidemiology and pathogenesis of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31800?source=related_link\">",
"      Male reproductive physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30423?source=related_link\">",
"      Steroid 5-alpha-reductase 2 deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_16_41221="Deferasirox: Patient drug information";
var content_f40_16_41221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Deferasirox: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/19/2360?source=see_link\">",
"     see \"Deferasirox: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/8/41094?source=see_link\">",
"     see \"Deferasirox: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1987209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Exjade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4432114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Exjade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705933",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad kidney and/or liver problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705930",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly stomach or bowel side effects like ulcers or bleeding. The risk may be greater in older people. This may occur without warning signs. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of iron when too much is in the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to deferasirox or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705957",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad kidney disease, very bad liver disease, or low platelets.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698499",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam before starting care and then one every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698492",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a hearing test before starting this drug and then every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696830",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bleeding may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hearing loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695890",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 30 minutes before a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix the tablet with fruit juice (orange, apple) or water until melted and drink right away. Do not chew or swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695597",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After drinking, rinse the rest of the drug in the glass with more juice or water and drink.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11527 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-59FAC149C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41221=[""].join("\n");
var outline_f40_16_41221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987209\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4432114\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026259\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026261\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026260\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026265\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026266\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026268\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026263\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026264\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026269\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026270\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/19/2360?source=related_link\">",
"      Deferasirox: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/8/41094?source=related_link\">",
"      Deferasirox: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_16_41222="Spinal manipulation in the treatment of musculoskeletal pain";
var content_f40_16_41222=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spinal manipulation in the treatment of musculoskeletal pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/16/41222/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41222/contributors\">",
"     Paul Shekelle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/16/41222/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41222/contributors\">",
"     Steven J Atlas, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/16/41222/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41222/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/16/41222/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal manipulation is a technique used by chiropractors, physical therapists, and osteopathic physicians, primarily to provide relief for musculoskeletal pain related to the back and neck. It has also been used for other conditions, which are discussed briefly below.",
"   </p>",
"   <p>",
"    This topic will focus on a description of spinal manipulation and a discussion of its effectiveness. Other discussions concerning the treatment of the patient with back",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neck pain is presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/21/13658?source=see_link\">",
"       \"Treatment of acute low back pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=see_link\">",
"       \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39753?source=see_link\">",
"       \"Subacute and chronic low back pain: Nonsurgical interventional treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34905?source=see_link\">",
"       \"Subacute and chronic low back pain: Surgical treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/43/6841?source=see_link\">",
"       \"Exercise-based therapy for low back pain\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SPINAL MANIPULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal manipulation is a form of manual therapy that involves the movement of a joint beyond its usual end range of motion but not past its anatomic range of motion, an area that has been termed the \"paraphysiologic zone.\" This movement of the joint is frequently accompanied by an audible cracking or popping sound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Types of manipulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;While definitions of what kinds of manual therapy are considered &ldquo;spinal manipulation&rsquo; are variable, one commonly used classification considers spinal manipulation to be one of two forms, depending upon the lever arm used to help the practitioner apply the load necessary for the manipulation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first type includes long-lever, low-velocity, or nonspecific manipulations; this form uses one of the long bones of the limbs (frequently the femur) to amplify the load applied by the clinician's hands to one or several spinal joints. These manipulations are associated primarily with the practice of osteopathy and physical therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The second type includes short-lever, high-velocity manipulations, or specific spinal adjustments; this form involves a short forceful thrust on a specific vertebral transverse process, thereby moving the specific joint. These manipulations are generally associated with the practice of chiropractic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Postulated mechanisms of benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four hypotheses have been proposed to explain the benefits of manipulation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Release of entrapped synovial folds or plica",
"     </li>",
"     <li>",
"      Relaxation of hypertonic muscle by sudden stretching",
"     </li>",
"     <li>",
"      Disruption of articular or periarticular adhesions",
"     </li>",
"     <li>",
"      Unblocking of motion segments that have undergone disproportionate displacements",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although some research supports each of these hypotheses, there is no convincing evidence proving the pathophysiologic mechanism underlying the benefit of spinal manipulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LOW BACK PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal manipulation is used for the treatment of both acute and chronic back pain. Manipulation is safe and probably effective for patients without radiculopathy, however, the beneficial effect may be minimal to modest on average [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Two meta-analyses compared spinal manipulation to a variety of other treatments, including general practitioner care, analgesics, physical therapy, exercises, or back school. The patient populations differed and findings were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with acute or chronic low back pain, a meta-analysis of 38 randomized trials concluded that there is no evidence that spinal manipulation is superior to other standard treatments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/4\">",
"       4",
"      </a>",
"      ]. Spinal manipulation was superior to sham therapy and to therapies that have been judged to be ineffective or harmful, but had no advantage when compared with the interventions above.",
"     </li>",
"     <li>",
"      A subsequent meta-analysis included 26 randomized trials in patients with chronic low back pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/5\">",
"       5",
"      </a>",
"      ]. Spinal manipulation was compared with multiple treatments, including those above as well as massage, ultrasound, transcutaneous muscle stimulation, and attending a pain clinic. This meta-analysis found high-quality evidence that spinal manipulation has a statistically significant, but not clinically significant, short-term effect on reducing pain and improving functional status, compared to other interventions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It may be possible to define subsets of patients in whom manipulation is likely to be beneficial. A randomized trial found that patients with low back pain were much more likely to benefit from manipulation plus exercise than from exercise alone, if they met at least four of the following criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms for fewer than 16 days",
"     </li>",
"     <li>",
"      No symptoms distal to the knee",
"     </li>",
"     <li>",
"      A score below 19 on the Fear-Avoidance Beliefs Questionnaire",
"     </li>",
"     <li>",
"      At least one hypomobile segment in the lumbar spine",
"     </li>",
"     <li>",
"      At least one hip with more than 35 degrees of internal rotation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, there are sufficient data to conclude that lumbar spinal manipulation is on average mildly effective for some patients with low back pain; the data are strongest for patients with acute uncomplicated low back pain. At present, we consider it appropriate to recommend manipulation as a therapeutic option to patients with uncomplicated low back pain who cannot take or tolerate other pain relieving measures (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or NSAIDs), those who responded well to manipulation in the past, or patients whose symptoms have persisted at an unacceptable level for more than 10 days. The effectiveness of manipulation relative to other forms of therapy remains a subject for ongoing research.",
"   </p>",
"   <p>",
"    Chiropractic care for low back pain probably costs more than supportive care provided by medical doctors, but it is also associated with enhanced patient satisfaction. The costs of chiropractic care and physical therapy are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/7\">",
"     7",
"    </a>",
"    ]. However, there are some data that patients who have insurance coverage for chiropractic care may have lower total health care expenditures, perhaps because of lower utilization of imaging and invasive procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/8\">",
"     8",
"    </a>",
"    ]; an alternative explanation for these data are that healthier patients may tend to choose a plan with chiropractic coverage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/9\">",
"     9",
"    </a>",
"    ]. No data exist to suggest that spinal manipulation can help prevent future back pain.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/21/13658?source=see_link\">",
"     \"Treatment of acute low back pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=see_link\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NECK PAIN AND HEADACHE",
"    </span>",
"    &nbsp;&mdash;&nbsp;After low back pain, neck pain and headache are the next most common symptoms for which spinal manipulative therapy is offered. Together, these symptoms account for about 20 percent of all visits to chiropractors. It is estimated that between 18 and 38 million cervical spine manipulations are performed annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Efficacy of manipulation for neck pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data supporting the efficacy of spinal manipulation for neck pain are more limited than those for low back pain, and the quality of these studies is insufficient to draw firm conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/12\">",
"     12",
"    </a>",
"    ]. As an example of studies in support of spinal manipulation, one randomized study compared physical therapist provided manipulation to nonmanipulative physical therapy, heat, or usual general practitioner care for patients with either nonspecific low back or neck pain syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/13\">",
"     13",
"    </a>",
"    ]. This study concluded that both physical therapist treated groups had better patient outcomes than the other two groups; in addition, the group receiving manipulation therapy did slightly better at one year than the group that received nonmanipulative physical therapy.",
"   </p>",
"   <p>",
"    Similarly, a randomized trial in the Netherlands that compared manual therapy (including cervical spine mobilization but not high-velocity manipulation) to either physical therapy or standard care by a general practitioner concluded that manual therapy was superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/14\">",
"     14",
"    </a>",
"    ]. At seven weeks, success rates for manual therapy, physical therapy, and care by a general practitioner were 68.3, 50.8, and 35.9 percent respectively. Manual therapy (that excluded spinal manipulation) was significantly less expensive than physical therapy or care by a general practitioner, making it more cost-effective than either [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a randomized trial comparing spinal manipulation, physiotherapy, and intensive training for patients with chronic neck pain found no difference among the three groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/16\">",
"     16",
"    </a>",
"    ]. Another randomized trial compared manual therapy that involved high velocity cervical spine manipulation with manual therapy that involved gentle neck mobilization over the patient's passive range of motion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/17\">",
"     17",
"    </a>",
"    ]. Manipulation was no better than gentle mobilization.",
"   </p>",
"   <p>",
"    A Cochrane review concluded that manipulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mobilization were not beneficial when done alone, but they were beneficial when used with exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/18\">",
"     18",
"    </a>",
"    ]. The review also concluded that neither manipulation nor mobilization was superior to the other and that there was insufficient evidence about their effects in patients with radicular findings. The review acknowledged the methodologic limitations of many of the underlying trials, and we feel that the evidence remains inadequate to draw firm conclusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Efficacy of manipulation for headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are very limited data supporting the use of manipulation of the cervical spine for headache. In one study, for example, the use of cervical spine manipulation for the treatment of episodic tension-type headache was found to be no better than soft tissue massage or placebo laser therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/19\">",
"     19",
"    </a>",
"    ]. A second short-term study of spinal manipulation for chronic tension-type headache reported statistically significant improvements for some but not all outcome measures in the manipulated group compared to a group of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two clinical trials of cervical spine manipulation for patients with migraine headache found no benefit compared to either spinal mobilization exercises or the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. A systematic review published in 2002 concluded that there were insufficient data to support the proposition that spinal manipulation is beneficial for treating headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the present time, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend manipulation of the cervical spine because the benefit is unproven and there are rare but serious adverse effects associated with neck manipulation. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Risks of spinal manipulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients treated with gentle mobilization appear to do as well as those treated with high-velocity manipulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OTHER CLINICAL CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial in 150 patients with shoulder pain and dysfunction found that compared with usual care, patients treated with manipulation of the cervical spine, upper thoracic spine, and adjacent ribs had higher rates of improvement after 12 weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/24\">",
"     24",
"    </a>",
"    ]. The study was unblinded and examined the primary outcome (patient perceived recovery) at a number of points in time without adjusting for multiple testing.",
"   </p>",
"   <p>",
"    Chiropractic spinal manipulation does not appear to provide additional clinical benefit for the medical treatment of asthma in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/25\">",
"     25",
"    </a>",
"    ]. At present, there are no compelling data supporting the efficacy of spinal manipulation for nonmusculoskeletal disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RISKS OF SPINAL MANIPULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, spinal manipulation is felt to be a relatively safe procedure, although it may be associated with a number of minor complaints and, rarely, serious adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Minor complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor complaints following spinal manipulation are common, with rates variably reported between 33 and 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/26\">",
"     26",
"    </a>",
"    ]. One systematic review of five prospective studies concluded that mild to moderate transient adverse reactions occurred in one-half of all patients undergoing spinal manipulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/27\">",
"     27",
"    </a>",
"    ]. In the largest series included in this review of 1058 patients treated by chiropractors, approximately 12, 11, and 50 percent of patients complained of headache, fatigue, and local discomfort at the site of the manipulation, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/28\">",
"     28",
"    </a>",
"    ]. Other less frequent complaints included dizziness, nausea, and hot skin. The causal relationship between spinal manipulation and any of these symptoms is unknown.",
"   </p>",
"   <p>",
"    A randomized trial of manipulation for neck pain found that low-velocity manipulation (mobilization) was somewhat less likely than high-velocity manipulation to lead to adverse reactions, however, adverse reactions were common in both groups, occurring in 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/29\">",
"     29",
"    </a>",
"    ]. Increased neck pain or stiffness was the most common adverse event, occurring in 25 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Serious adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common serious adverse events associated with spinal manipulation include disk herniation, the cauda equina syndrome, and vertebrobasilar accidents. Estimates of the incidence of these complications range from 1 per 2 million to 1 per 400,000 manipulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/30\">",
"     30",
"    </a>",
"    ]. These estimates are primarily derived from published case reports, case series, and retrospective surveys, all of which may be unreliable due to underreporting and the dependence on recall.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disk herniation and the cauda equina syndrome occur most commonly with lumbar manipulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/31\">",
"       31",
"      </a>",
"      ]. Individuals with a herniated nucleus pulposus or an underlying bleeding disorder are postulated to be at increased risk of the cauda equina syndrome.",
"     </li>",
"     <li>",
"      Vertebrobasilar artery ischemic events occur after cervical manipulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/32\">",
"       32",
"      </a>",
"      ]. Some reports estimate it to occur as infrequently as once per 1 to 3 million manipulations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/12\">",
"       12",
"      </a>",
"      ], while others report an incidence as high as 5 per 100,000 manipulations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A six-week prospective study of cervical spine manipulation involved 377 chiropractors in Britain (32 percent of the country's chiropractors, although all were invited to participate) and over 19,000 patients and 50,000 cervical manipulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/33\">",
"     33",
"    </a>",
"    ]. No serious adverse events were reported by clinicians or patients in this timeframe, although underreporting was possible both due to loss to follow-up for 413 consultations, and potential bias introduced by self-reporting.",
"   </p>",
"   <p>",
"    Several case control studies have examined the association of vertebrobasilar dissection or occlusion and spinal manipulation. While an association has been reported, the causality between manipulation and dissection has not been established. Representative studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A population-based, case-control study found that in patients under the age of 45, those with vertebrobasilar dissection or occlusion were five times more likely than controls to have visited a chiropractor in the previous week and to have had three or more cervical chiropractic visits in the previous month [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/34\">",
"       34",
"      </a>",
"      ]. No association between chiropractic and vertebrobasilar events was found for older individuals.",
"     </li>",
"     <li>",
"      A case-control study of patients younger than 60 presenting with a stroke or transient ischemic attack found a higher rate of spinal manipulation within the previous 30 days in patients whose event was due to a vertebral arterial dissection than in patients with an event due to another etiology (OR 6.62, 95% CI 1.4-30) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, another case control study of vertebrobasilar stroke in persons under the age of 45 found that patients were three times more likely than controls to have visited a chiropractor or to have visited a primary care clinician prior to their stroke; the authors postulate that visits to a health care provider are a marker for impending VBA and possibly not causally related [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41222/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A paucity of data exists concerning the risk factors for vertebrobasilar compromise after manipulation. Anecdotal evidence suggests that the risk is higher for manipulation involving rotation plus extension of the cervical spine than for other types of manipulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many case reports describing complications due to misdiagnosis by providers who perform spinal manipulation, such as failing to correctly diagnose spinal tumors or metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spinal manipulation is a form of manual therapy that involves the movement of a joint beyond its usual end range of motion but not past its anatomic range of motion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Spinal manipulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumbar spinal manipulation is probably mildly effective for patients with uncomplicated low back pain who cannot take or tolerate other pain relieving measures such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or NSAIDs, those who responded well to manipulation in the past, or patients whose symptoms have persisted at an unacceptable level for more than 10 days. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Low back pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are limited data to support the use of manipulation of the cervical spine for neck pain and headache. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Neck pain and headache'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spinal manipulation of the lumbar spine is felt to be a relatively safe procedure, although it may be associated with a number of minor complaints and, rarely, serious adverse events. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risks of spinal manipulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Maitland GD. Vertebral manipulation, Butterworths, London 1964.",
"    </li>",
"    <li>",
"     Paris SV. The spinal lesion, Pegasus Press, Auckland 1965.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/3\">",
"      Cherkin DC, Sherman KJ, Deyo RA, Shekelle PG. A review of the evidence for the effectiveness, safety, and cost of acupuncture, massage therapy, and spinal manipulation for back pain. Ann Intern Med 2003; 138:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/4\">",
"      Assendelft WJ, Morton SC, Yu EI, et al. Spinal manipulative therapy for low back pain. A meta-analysis of effectiveness relative to other therapies. Ann Intern Med 2003; 138:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/5\">",
"      Rubinstein SM, van Middelkoop M, Assendelft WJ, et al. Spinal manipulative therapy for chronic low-back pain. Cochrane Database Syst Rev 2011; :CD008112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/6\">",
"      Childs JD, Fritz JM, Flynn TW, et al. A clinical prediction rule to identify patients with low back pain most likely to benefit from spinal manipulation: a validation study. Ann Intern Med 2004; 141:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/7\">",
"      Skargren EI, Carlsson PG, Oberg BE. One-year follow-up comparison of the cost and effectiveness of chiropractic and physiotherapy as primary management for back pain. Subgroup analysis, recurrence, and additional health care utilization. Spine (Phila Pa 1976) 1998; 23:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/8\">",
"      Legorreta AP, Metz RD, Nelson CF, et al. Comparative analysis of individuals with and without chiropractic coverage: patient characteristics, utilization, and costs. Arch Intern Med 2004; 164:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/9\">",
"      Ness J, Nisly N. Cracking the problem of back pain: is chiropractic the answer? Arch Intern Med 2004; 164:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/10\">",
"      Shekelle PG, Brook RH. A community-based study of the use of chiropractic services. Am J Public Health 1991; 81:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/11\">",
"      Hurwitz EL, Coulter ID, Adams AH, et al. Use of chiropractic services from 1985 through 1991 in the United States and Canada. Am J Public Health 1998; 88:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/12\">",
"      Hurwitz EL, Aker PD, Adams AH, et al. Manipulation and mobilization of the cervical spine. A systematic review of the literature. Spine (Phila Pa 1976) 1996; 21:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/13\">",
"      Koes BW, Bouter LM, van Mameren H, et al. Randomised clinical trial of manipulative therapy and physiotherapy for persistent back and neck complaints: results of one year follow up. BMJ 1992; 304:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/14\">",
"      Hoving JL, Koes BW, de Vet HC, et al. Manual therapy, physical therapy, or continued care by a general practitioner for patients with neck pain. A randomized, controlled trial. Ann Intern Med 2002; 136:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/15\">",
"      Korthals-de Bos IB, Hoving JL, van Tulder MW, et al. Cost effectiveness of physiotherapy, manual therapy, and general practitioner care for neck pain: economic evaluation alongside a randomised controlled trial. BMJ 2003; 326:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/16\">",
"      Jordan A, Bendix T, Nielsen H, et al. Intensive training, physiotherapy, or manipulation for patients with chronic neck pain. A prospective, single-blinded, randomized clinical trial. Spine (Phila Pa 1976) 1998; 23:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/17\">",
"      Hurwitz EL, Morgenstern H, Harber P, et al. A randomized trial of chiropractic manipulation and mobilization for patients with neck pain: clinical outcomes from the UCLA neck-pain study. Am J Public Health 2002; 92:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/18\">",
"      Gross AR, Hoving JL, Haines TA, et al. A Cochrane review of manipulation and mobilization for mechanical neck disorders. Spine (Phila Pa 1976) 2004; 29:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/19\">",
"      Bove G, Nilsson N. Spinal manipulation in the treatment of episodic tension-type headache: a randomized controlled trial. JAMA 1998; 280:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/20\">",
"      Boline PD, Kassak K, Bronfort G, et al. Spinal manipulation vs. amitriptyline for the treatment of chronic tension-type headaches: a randomized clinical trial. J Manipulative Physiol Ther 1995; 18:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/21\">",
"      Parker GB, Tupling H, Pryor DS. A controlled trial of cervical manipulation of migraine. Aust N Z J Med 1978; 8:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/22\">",
"      Nelson CF, Bronfort G, Evans R, et al. The efficacy of spinal manipulation, amitriptyline and the combination of both therapies for the prophylaxis of migraine headache. J Manipulative Physiol Ther 1998; 21:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/23\">",
"      Astin JA, Ernst E. The effectiveness of spinal manipulation for the treatment of headache disorders: a systematic review of randomized clinical trials. Cephalalgia 2002; 22:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/24\">",
"      Bergman GJ, Winters JC, Groenier KH, et al. Manipulative therapy in addition to usual medical care for patients with shoulder dysfunction and pain: a randomized, controlled trial. Ann Intern Med 2004; 141:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/25\">",
"      Balon J, Aker PD, Crowther ER, et al. A comparison of active and simulated chiropractic manipulation as adjunctive treatment for childhood asthma. N Engl J Med 1998; 339:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/26\">",
"      Gouveia LO, Castanho P, Ferreira JJ. Safety of chiropractic interventions: a systematic review. Spine (Phila Pa 1976) 2009; 34:E405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/27\">",
"      Ernst E. Prospective investigations into the safety of spinal manipulation. J Pain Symptom Manage 2001; 21:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/28\">",
"      Senstad O, Leboeuf-Yde C, Borchgrevink C. Frequency and characteristics of side effects of spinal manipulative therapy. Spine (Phila Pa 1976) 1997; 22:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/29\">",
"      Hurwitz EL, Morgenstern H, Vassilaki M, Chiang LM. Frequency and clinical predictors of adverse reactions to chiropractic care in the UCLA neck pain study. Spine (Phila Pa 1976) 2005; 30:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/30\">",
"      Stevinson C, Ernst E. Risks associated with spinal manipulation. Am J Med 2002; 112:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/31\">",
"      Shekelle PG, Adams AH, Chassin MR, et al. Spinal manipulation for low-back pain. Ann Intern Med 1992; 117:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/32\">",
"      Hufnagel A, Hammers A, Sch&ouml;nle PW, et al. Stroke following chiropractic manipulation of the cervical spine. J Neurol 1999; 246:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/33\">",
"      Thiel HW, Bolton JE, Docherty S, Portlock JC. Safety of chiropractic manipulation of the cervical spine: a prospective national survey. Spine (Phila Pa 1976) 2007; 32:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/34\">",
"      Rothwell DM, Bondy SJ, Williams JI. Chiropractic manipulation and stroke: a population-based case-control study. Stroke 2001; 32:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/35\">",
"      Smith WS, Johnston SC, Skalabrin EJ, et al. Spinal manipulative therapy is an independent risk factor for vertebral artery dissection. Neurology 2003; 60:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41222/abstract/36\">",
"      Cassidy JD, Boyle E, C&ocirc;t&eacute; P, et al. Risk of vertebrobasilar stroke and chiropractic care: results of a population-based case-control and case-crossover study. Spine (Phila Pa 1976) 2008; 33:S176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7776 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41222=[""].join("\n");
var outline_f40_16_41222=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SPINAL MANIPULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Types of manipulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Postulated mechanisms of benefit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LOW BACK PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NECK PAIN AND HEADACHE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Efficacy of manipulation for neck pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Efficacy of manipulation for headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OTHER CLINICAL CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RISKS OF SPINAL MANIPULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Minor complaints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Serious adverse events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/43/6841?source=related_link\">",
"      Exercise-based therapy for low back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39753?source=related_link\">",
"      Subacute and chronic low back pain: Nonsurgical interventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=related_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34905?source=related_link\">",
"      Subacute and chronic low back pain: Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/21/13658?source=related_link\">",
"      Treatment of acute low back pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_16_41223="Ganglia and nodules";
var content_f40_16_41223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ganglia and nodules",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/16/41223/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41223/contributors\">",
"     Robert P Sheon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41223/contributors\">",
"     Filip De Keyser, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/16/41223/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41223/contributors\">",
"     Zacharia Isaac, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/16/41223/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41223/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/16/41223/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue masses are usually benign and of little clinical consequence. However, benign lesions such as ganglia and nodules may interfere with joint function and, therefore, require treatment. The differential diagnosis of nodular soft tissue masses is extensive and includes a number of systemic diseases and solid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/1\">",
"     1",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef69807 graphicRef82043 \" href=\"mobipreview.htm?9/50/10030\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GANGLIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A ganglion is a cystic swelling overlying a joint or tendon sheath. Ganglia are thought to arise due to herniation of synovial tissue from a joint capsule or tendon sheath. They represent myxoid degeneration and may be of congenital origin. The role, if any, of repetitive movement in causation is uncertain; it may induce enlargement of the lesion and may provoke symptoms.",
"   </p>",
"   <p>",
"    Common locations for ganglia include the wrist and tissue adjacent to finger joints (",
"    <a class=\"graphic graphic_picture graphicRef65578 \" href=\"mobipreview.htm?31/35/32318\">",
"     picture 1",
"    </a>",
"    ). They also occur over the dorsum of the foot and, less often, may arise in the knee, in the shoulder, in the spine, or in other intraarticular, extraarticular soft tissue, intraosseous, or periosteal locations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The lesions may be unilocular or multilocular. A jelly-like fluid can be aspirated from the lesion.",
"   </p>",
"   <p>",
"    Ganglia may present as an obvious swelling on physical examination or may only be manifested by joint (particularly wrist) pain. Most wrist ganglia originate from the palmar capsule near the radioscaphocapitate ligament and are not caused by ligamentous disruption, soft tissue edema, or intraosseous communication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic approach depends upon the physical examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with a readily palpable lesion, transillumination provides an easy in-office method for differentiating ganglia from solid tumors; ganglia transilluminate while solid tumors do not. Many surgeons will remove palpable ganglia on the basis of transillumination results and do not require radiologic tests.",
"     </li>",
"     <li>",
"      Ultrasonography is useful in the diagnosis of ganglia. Most ganglia have well-defined margins, thick walls, and acoustic enhancement. A solid-appearing ganglion, although unusual, may mimic a benign neoplasm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with occult wrist pain, magnetic resonance imaging (MRI) can differentiate most ganglia from other types of masses. One study of 14 patients with chronic dorsal wrist pain of unknown etiology, for example, found that the positive predictive value of MRI was 100 percent for the diagnosis of occult ganglia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/6\">",
"       6",
"      </a>",
"      ]. However, many MR abnormalities and variants may be detected in the wrists of asymptomatic subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/7\">",
"       7",
"      </a>",
"      ]. These could be confused with pathologic findings usually associated with inflammatory arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/7\">",
"       7",
"      </a>",
"      ]. Ultrasonography is an alternative technique for detecting ganglion cysts in patients with wrist pain of unclear etiology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ganglia may spontaneously regress or recur. Thus, expectant management is appropriate if the mass is not painful or is not interfering with function. When symptomatic, treatment options include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aspiration and injection of a crystalline glucocorticoid. A 10 mL syringe with a 16 gauge needle is usually necessary to allow the highly viscous fluid to be aspirated. Optimal aspiration occurs at the base of the ganglion. Single versus multiple needle punctures were compared in one study, and both methods provided relief. Only 18 percent of patients subsequently requested surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intralesional",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/33/42512?source=see_link\">",
"       hyaluronidase",
"      </a>",
"      injection (up to 150 units in 1 mL), followed by fine needle aspiration. In one study, this approach resulted in cure at six months in 95 percent of 349 treated hand and wrist ganglia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surgical removal of the ganglion and repair of the defect after tracing its connection to the tendon sheath or capsule. Surgery is generally quite effective; however, if not properly removed, the ganglion may recur postoperatively. Approximately 10 percent recur with either standard or arthroscopic surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/12\">",
"       12",
"      </a>",
"      ]. Office methods of treatment should precede surgical excision.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NODULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of nodules includes those associated with repetitive trauma, tumors, and a number of systemic diseases (",
"    <a class=\"graphic graphic_table graphicRef69807 graphicRef82043 \" href=\"mobipreview.htm?9/50/10030\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35541?source=see_link\">",
"     \"Approach to dermatologic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Xanthomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;These pinkish, yellow papules may be the first evidence of hyperlipidemia. Usually asymptomatic and bilateral, they may occur abruptly (eruptive xanthomas) over pressure points and extensor surfaces or gradually over Achilles, patellar, and digital extensor tendons. Often, the patient pays no attention to them; the clinician may be the first to realize their significance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Polyfibromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of nodular plantar fibromatosis with induration of the plantar aponeurosis leading to contractures (similar to Dupuytren&rsquo;s contractures of the hand) is known as Ledderhose syndrome or Ledderhose contracture. Other features that may coexist include frozen shoulder and Peyronie&rsquo;s disease. An erosive arthropathy with significant limitation of movement at affected joints may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/13\">",
"     13",
"    </a>",
"    ]. Some cases are linked to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    and to diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The constellation of cutaneous fibrosis at several sites (eg, Dupuytren&rsquo;s contracture, plantar fibromatosis, and keloid formation) has been referred to as polyfibromatosis. Although more commonly seen adults, polyfibromatosis may occur in childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of plantar fibromatosis should begin with injecting the plantar fibromas with a glucocorticoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/17\">",
"     17",
"    </a>",
"    ]. Several injections (one a month or less often) may be necessary, and the clinical response may be inadequate, leading to surgical excision. Recurrence is common. Soft shoe inserts with cutouts where nodules impact can provide some comfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fibroblastic rheumatism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibroblastic rheumatism is a rare disease of unknown etiology. Fibroblastic rheumatism shares the features of arthralgia, arthritis, and nodules. Flexion contractures of the fingers occur in most patients, while thickened palmar fascia is noted in about one-half of reported cases. Biopsy of a nodule or thickened skin typically reveals increased thickness of collagen fibers and fibroblastic proliferation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nodules associated with repetitive trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of nodules may arise from repetitive trauma. &ldquo;Surfer&rsquo;s nodules,&rdquo; for example, tend to occur in the pretibial foreleg region and may resemble rheumatoid nodules. They result from activities in which the foreleg and the hyperextended ankle are recurrently brought into contact with the hard surface of the surfboard. Similarly, &ldquo;painter&rsquo;s bosses&rdquo; are nodules in which the foreleg strikes the rungs of a ladder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/18\">",
"     18",
"    </a>",
"    ]. Nodules can also occur on children&rsquo;s forefeet if they repeatedly sit on their legs with their feet in plantar flexion and in contact with hardwood floors. Avoiding surface contact is curative in all of these cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Silicone and other injectables",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical use of silicone may be associated with the appearance of nodular lesions at the site of injection as well as at a distance. Granulomatous tissue reaction after hyaluronic acid injection may evolve into abscesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/19\">",
"     19",
"    </a>",
"    ]. Subcutaneous injection or infiltration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/20\">",
"     20",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    , and hypertonic glucose can also cause nodules and granulomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Epidermoid cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermoid cysts or pearls are small, hard, pearl-like cysts that are several millimeters in diameter. They tend to disappear spontaneously over time. The most common locations are the volar aspect of the distal phalanx of the index or middle finger or are within the interdigital webs. They are rarely larger than 1 centimeter and do",
"    <strong>",
"     not",
"    </strong>",
"    transilluminate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipomas, fibromas, neuromas, dorsal exostoses, periarticular calcaneus deposits, giant cell tumors, and synovial cysts are additional benign lesions that can occur as solitary or multiple lesions. Sarcomas are rare. However, metastatic lesions to the digits can occur, and cutaneous and subcutaneous nodules may result from infiltration of metastatic tumor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple, sometimes painful, lipomas are characteristic of the rare disorder, lipomatosis dolorosa (adiposis dolorosa, Dercum&rsquo;s disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/22\">",
"     22",
"    </a>",
"    ]. Despite the presence of pain, the lipomas are not associated with histopathologic evidence of inflammation as would be expected in panniculitis. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Panniculitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     AIDS-related Kaposi's sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous lesions in this condition appear most often on the lower extremities, face (especially the nose), oral mucosa, and genitalia. The lesions are often elliptical and may be arranged in a linear fashion along skin tension lines; they may be symmetrically distributed. The lesions are not painful or pruritic and usually do not produce necrosis of overlying skin or of underlying structures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sweet syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sweet syndrome (the eponym for acute febrile neutrophilic dermatosis) is characterized by a constellation of clinical symptoms, physical features, and pathologic findings which include fever, neutrophilia, tender erythematous skin lesions (papules, nodules, and plaques), and a diffuse infiltrate consisting predominantly of mature neutrophils that are typically located in the upper dermis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40905?source=see_link\">",
"     \"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rheumatoid nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid nodules are firm, nontender, flesh-colored, subcutaneous lesions that occur in approximately 20 percent of patients with rheumatoid arthritis (RA), primarily those who are rheumatoid factor positive. Rheumatoid nodules may be fixed or movable and are found most commonly over pressure points such as the elbow and extensor surface of the proximal ulna. Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    may induce an acceleration of nodule formation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .) The pathology, pathogenesis, diagnosis, and treatment of rheumatoid nodules are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/7/29815?source=see_link\">",
"     \"Rheumatoid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Rheumatic fever nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous nodules may be seen in association with acute rheumatic fever. Rheumatic subcutaneous nodules generally appear only after the first weeks of illness and usually occur only in patients with carditis. They generally have the following characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nodules are firm and painless.",
"     </li>",
"     <li>",
"      The overlying skin is not inflamed and can usually be moved over the nodules.",
"     </li>",
"     <li>",
"      The diameter varies from a few millimeters to 1 or 2 centimeters.",
"     </li>",
"     <li>",
"      The nodules are most commonly located over a bony surface or prominence or near tendons.",
"     </li>",
"     <li>",
"      The number of nodules varies from a single lesion to a few dozen and averages three or four; when numerous, the nodules are usually symmetric.",
"     </li>",
"     <li>",
"      Nodules are present for one or more weeks, rarely for more than a month.",
"     </li>",
"     <li>",
"      They are smaller and more short-lived than the nodules of rheumatoid arthritis. Furthermore, although the elbows are most frequently involved in both diseases, rheumatic fever nodules are more common on the olecranon, while rheumatoid nodules are usually found 3 to 4 centimeters distally.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pseudorheumatoid nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;These lesions occur in the pretibial region in infants and children. No articular abnormalities are seen, and the nodule is painless. No treatment is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Tophi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uric acid deposits can produce firm subcutaneous nodules in patients with gout. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    .) They typically originate at the joint margin and may be yellow with overlying erythema when close to the surface. Tophi can occur at any site; the most common locations are the digits of the hands and feet and, less commonly, the helix or antihelix of the ear.",
"   </p>",
"   <p>",
"    Tophi are typically not painful or tender. However, a chronic granulomatous inflammatory response is identifiable on histologic examination of the lesions, and, on occasion, acute inflammation mimicking that of gouty arthritis occurs in one or several tophi (",
"    <a class=\"graphic graphic_picture graphicRef73021 \" href=\"mobipreview.htm?25/60/26575\">",
"     picture 2",
"    </a>",
"    ). If painful, large, and inflamed, they may regress quickly with an intralesional glucocorticoid injection as well as proper systemic medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Panniculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panniculitis is inflammation within adipose tissue that typically affects the subcutaneous fat. A number of conditions can be associated with panniculitis, with or without an associated vasculitis. In contrast to nodules associated with rheumatic disease, these lesions tend to be red and to be tender or painful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=see_link\">",
"     \"Panniculitis: Recognition and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodular vasculitis (erythema induratum) is a lobular panniculitis with local vasculitis. It may be idiopathic, due to infectious agents (eg, tuberculosis or histoplasmosis) or to hypersensitivity to foreign material. It presents as red and tender subcutaneous nodules, commonly on the calf; these lesions tend to ulcerate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/24\">",
"       24",
"      </a>",
"      ]. Erythema induratum has also been associated with hepatitis C infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Weber-Christian disease is a term historically used for an idiopathic lobular panniculitis that presents with fever, polyarthralgias, and painful subcutaneous nodules. The nodules may ulcerate or scar, which is associated with fat necrosis. There is uncertainty regarding whether this condition exists as a distinct entity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=see_link\">",
"       \"Panniculitis: Recognition and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pancreatic or enzymatic panniculitis is associated with pancreatitis and pancreatic carcinoma; in these cases, fat necrosis is induced by liberated enzymes. A small number of patients with alpha-1 antitrypsin deficiency also develop panniculitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link&amp;anchor=H5#H5\">",
"       \"Cutaneous manifestations of internal malignancy\", section on 'Pancreatic panniculitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18136?source=see_link\">",
"       \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lupus profundus represents a firm nodular lesion with or without an overlying cutaneous lesion. When the nodules occur without skin lesions, they are called lupus panniculitis. The nodules may appear on the scalp, face, arms, chest, back, thighs, and buttocks. They usually resolve but may leave a depressed area (",
"      <a class=\"graphic graphic_picture graphicRef83791 \" href=\"mobipreview.htm?1/15/1264\">",
"       picture 3",
"      </a>",
"      ). Ulcerations are uncommon. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Erythema nodosum lesions are symmetrical red or violet subcutaneous nodules, which are 1 to 5 cm in diameter; they are characterized histologically by septal panniculitis without vasculitis. The lesions are deep nodules which may be more easily palpated than visualized. They usually develop in a pretibial location and regress spontaneously in several weeks to lesions which resemble a bruise or contusion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13130?source=see_link\">",
"       \"Erythema nodosum\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Erythema nodosum may be associated with fever, malaise, and an acute polyarthritis. It may be idiopathic, is rarely familial, and may be associated with infections, drugs, or systemic diseases (",
"      <a class=\"graphic graphic_table graphicRef63580 \" href=\"mobipreview.htm?6/23/6524\">",
"       table 2",
"      </a>",
"      ). Erythema nodosum has been reported in three patients receiving aromatase inhibitor (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"       anastrozole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"       exemestane",
"      </a>",
"      ) treatment of breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/26\">",
"       26",
"      </a>",
"      ]. Echinacea herbal therapy has also been followed by erythema nodosum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular subcutaneous sarcoidosis is a rare manifestation of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/28\">",
"     28",
"    </a>",
"    ]. More typical dermatologic findings are waxy papules on the face and trunk, as well as painful, tender lesions of erythema nodosum, most often on the lower extremities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Dermatologic'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purpura, palpable purpura, livedo, nodules, urticaria, skin necrosis, and oral and genital ulcers are features of a variety of systemic vasculitides. Polyarteritis nodosa can be associated with painful cutaneous and subcutaneous nodules that may ulcerate. They develop in crops and are found most often on the lower legs and feet. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nodular skin lesions with histologic features similar to those of nodular vasculitis may occur in patients with Beh&ccedil;et&rsquo;s disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/29\">",
"     29",
"    </a>",
"    ]. The subcutaneous neutrophil infiltration and associated small vessel vasculitis are easily distinguished from the panniculitis of erythema nodosum. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Panniculitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Atypical infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint or tendon sheath infections may be associated with adjacent nodules that often ulcerate. These infections include atypical mycobacterial infections, sporotrichosis, and treponemal infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphadenopathy must be distinguished from other causes of subcutaneous nodules. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39080?source=see_link\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30744?source=see_link&amp;anchor=H5#H5\">",
"     \"Causes of peripheral lymphadenopathy in children\", section on 'Overview'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the child with peripheral lymphadenopathy\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions may present as isolated nodules, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cubital bursitis and antecubital cysts can cause swelling and pain at the anteromedial border of the elbow or in the antecubital area. Repetitive movement and a roughened surface of the bicipital tuberosity are thought to contribute to the formation of these lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. The median nerve may be stretched by the swelling, causing pain to radiate into the forearm and hand. Aspiration and injection with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      acetate 20 mg and 1 mL of 1 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      hydrochloride are often helpful, although excision may be required.",
"     </li>",
"     <li>",
"      Herniation of the tibialis anterior muscle may present with a painful nodule in the anterolateral lower foreleg. These nodules are more evident during weightbearing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41223/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT WITH A NODULAR LESION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The broad differential of nodular lesions can often be narrowed considerably after a careful history and physical examination. The characteristic features of many of these lesions are summarized in the tables (",
"    <a class=\"graphic graphic_table graphicRef69807 graphicRef82043 \" href=\"mobipreview.htm?9/50/10030\">",
"     table 1A-B",
"    </a>",
"    ). The following questions need to be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are lesions scattered or solitary? Tumors and noninflammatory nodules tend to be solitary, while infectious and inflammatory lesions are often multiple.",
"     </li>",
"     <li>",
"      Are there signs and symptoms of systemic disease (eg, infection or inflammatory disease)?",
"     </li>",
"     <li>",
"      Has the patient had previous lesions that have disappeared (eg, erythema nodosum or acute rheumatic fever nodules)?",
"     </li>",
"     <li>",
"      Has the lesion changed in appearance since discovery? Ganglia tend not to change, while sarcomas change rather rapidly.",
"     </li>",
"     <li>",
"      Has the patient received any injectable medication or tissue expanding substance at or near the site (eg, silicone)?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Helpful websites include:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://en.diagnosispro.com/differential_diagnosis-for/subcutaneous-nodules/33784-154.html\">",
"     file://en.diagnosispro.com/differential_diagnosis-for/subcutaneous-nodules/33784-154.html",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://dermatlas.med.jhmi.edu/derm/index.cfm\">",
"     file://dermatlas.med.jhmi.edu/derm/index.cfm",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/21/338?source=see_link\">",
"       \"Patient information: Ganglion cyst (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1122984\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Soft tissue masses are usually benign and are of little clinical consequence. Treatment may be needed if benign lesions such as ganglia and nodules interfere with joint function. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A ganglion is a cystic unilocular or multilocular swelling overlying a joint or tendon sheath, which is thought to arise due to herniation of synovial tissue from a joint capsule or tendon sheath and to represent myxoid degeneration. Common locations for ganglia include the wrist and tissue adjacent to finger joints, but they can also occur in other intra-articular, extra-articular soft tissue, intraosseous, or periosteal locations. A jelly-like fluid can be aspirated from the lesion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ganglia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic approach to ganglia depends upon the physical examination. Ganglia may present as an obvious swelling on physical examination and may be differentiated from a solid tumor by transillumination or ultrasonography. Other ganglia may only be manifested by joint (particularly wrist) pain; magnetic resonance imaging can differentiate most ganglia from other types of masses. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ganglia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ganglia may spontaneously regress or recur. Thus, expectant management is appropriate if the mass is not painful or is not interfering with function. When symptomatic, treatment options include aspiration and injection of a crystalline glucocorticoid, usually at the base of the ganglion; intralesional",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/33/42512?source=see_link\">",
"       hyaluronidase",
"      </a>",
"      injection, followed by fine needle aspiration; and surgical removal of the ganglion and repair of the defect. Office methods of treatment should precede surgical excision. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of nodular soft tissue masses is extensive and includes nodules associated with repetitive trauma, a number of systemic diseases, and solid tumors (",
"      <a class=\"graphic graphic_table graphicRef69807 graphicRef82043 \" href=\"mobipreview.htm?9/50/10030\">",
"       table 1A-B",
"      </a>",
"      ). The broad differential of nodular lesions can often be narrowed considerably after a careful history and physical examination. The following questions should be addressed (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Nodules'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Approach to the patient with a nodular lesion'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Are lesions scattered or solitary? Tumors and noninflammatory nodules tend to be solitary, while infectious and inflammatory lesions are often multiple.",
"     </li>",
"     <li>",
"      Are there signs and symptoms of systemic disease (eg, infection or inflammatory disease)?",
"     </li>",
"     <li>",
"      Has the patient had previous lesions that have disappeared (eg, erythema nodosum or acute rheumatic fever nodules)?",
"     </li>",
"     <li>",
"      Has the lesion changed in appearance since discovery? Ganglia tend not to change, while sarcomas change rather rapidly.",
"     </li>",
"     <li>",
"      Has the patient received any injectable medication or tissue expanding substance at or near the site (eg, silicone or hyaluronic acid)?",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/1\">",
"      Handa R, Verma K, D'Souza P. Cutaneous nodules in a patient with polyarthritis. Postgrad Med J 1999; 75:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/2\">",
"      Steiner E, Steinbach LS, Schnarkowski P, et al. Ganglia and cysts around joints. Radiol Clin North Am 1996; 34:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/3\">",
"      McCarthy CL, McNally EG. The MRI appearance of cystic lesions around the knee. Skeletal Radiol 2004; 33:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/4\">",
"      Lowden CM, Attiah M, Garvin G, et al. The prevalence of wrist ganglia in an asymptomatic population: magnetic resonance evaluation. J Hand Surg Br 2005; 30:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/5\">",
"      Teefey SA, Dahiya N, Middleton WD, et al. Ganglia of the hand and wrist: a sonographic analysis. AJR Am J Roentgenol 2008; 191:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/6\">",
"      Vo P, Wright T, Hayden F, et al. Evaluating dorsal wrist pain: MRI diagnosis of occult dorsal wrist ganglion. J Hand Surg Am 1995; 20:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/7\">",
"      Robertson PL, Page PJ, McColl GJ. Inflammatory arthritis-like and other MR findings in wrists of asymptomatic subjects. Skeletal Radiol 2006; 35:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/8\">",
"      Backhaus M, Schmidt WA, Mellerowicz H, et al. [Technique and diagnostic value of musculoskeletal ultrasonography in rheumatology. Part 6: ultrasonography of the wrist/hand]. Z Rheumatol 2002; 61:674.",
"     </a>",
"    </li>",
"    <li>",
"     Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd, Williams &amp; Wilkins, Baltimore 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/10\">",
"      Stephen AB, Lyons AR, Davis TR. A prospective study of two conservative treatments for ganglia of the wrist. J Hand Surg Br 1999; 24:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/11\">",
"      Otu AA. Wrist and hand ganglion treatment with hyaluronidase injection and fine needle aspiration: a tropical African perspective. J R Coll Surg Edinb 1992; 37:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/12\">",
"      Kang L, Akelman E, Weiss AP. Arthroscopic versus open dorsal ganglion excision: a prospective, randomized comparison of rates of recurrence and of residual pain. J Hand Surg Am 2008; 33:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/13\">",
"      Kim SK, Kim HJ, Lee YH, et al. Erosive arthropathy with osteolysis as a typical feature in polyfibromatosis syndrome: a case report and a review of the literature. J Korean Med Sci 2009; 24:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/14\">",
"      Elhadd TA, Ghosh S, Malik MI, Collier A. Plantar fibromatosis and Dupuytren's disease: an association to remember in patients with diabetes. Diabet Med 2007; 24:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/15\">",
"      Strzelczyk A, Vogt H, Hamer HM, Kr&auml;mer G. Continuous phenobarbital treatment leads to recurrent plantar fibromatosis. Epilepsia 2008; 49:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/16\">",
"      Fetsch JF, Laskin WB, Miettinen M. Palmar-plantar fibromatosis in children and preadolescents: a clinicopathologic study of 56 cases with newly recognized demographics and extended follow-up information. Am J Surg Pathol 2005; 29:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/17\">",
"      Pentland AP, Anderson TF. Plantar fibromatosis responds to intralesional steroids. J Am Acad Dermatol 1985; 12:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/18\">",
"      Ehrlich GE. Painter's bosses. Arch Intern Med 1965; 116:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/19\">",
"      H&ouml;nig JF, Brink U, Korabiowska M. Severe granulomatous allergic tissue reaction after hyaluronic acid injection in the treatment of facial lines and its surgical correction. J Craniofac Surg 2003; 14:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/20\">",
"      Funt SA, Hidalgo A, Panicek DM. Subcutaneous nodules at the injection site of low-molecular-weight heparin: a mimic of metastatic disease at CT. J Comput Assist Tomogr 2002; 26:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/21\">",
"      Fogel GR, Younge DA, Dobyns JH. Pitfalls in the diagnosis of the simple wrist ganglion. Orthopedics 1983; 6:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/22\">",
"      Campen RB, Sang CN, Duncan LM. Case records of the Massachusetts General Hospital. Case 25-2006. A 41-year-old woman with painful subcutaneous nodules. N Engl J Med 2006; 355:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/23\">",
"      BALDWIN JS, KERR JM, KUTTNER AG, DOYLE EF. Observations on rheumatic nodules over a 30-year period. J Pediatr 1960; 56:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/24\">",
"      Pottage JC Jr, Trenholme GM, Aronson IK, Harris AA. Panniculitis associated with histoplasmosis and alpha 1-antitrypsin deficiency. Am J Med 1983; 75:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/25\">",
"      Fernandes SS, Carvalho J, Leite S, et al. Erythema induratum and chronic hepatitis C infection. J Clin Virol 2009; 44:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/26\">",
"      Jhaveri K, Halperin P, Shin SJ, Vahdat L. Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature. Breast Cancer Res Treat 2007; 106:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/27\">",
"      Soon SL, Crawford RI. Recurrent erythema nodosum associated with Echinacea herbal therapy. J Am Acad Dermatol 2001; 44:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/28\">",
"      Heller M, Soldano AC. Sarcoidosis with subcutaneous lesions. Dermatol Online J 2008; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/29\">",
"      Demirkesen C, T&uuml;z&uuml;ner N, Mat C, et al. Clinicopathologic evaluation of nodular cutaneous lesions of Beh&ccedil;et syndrome. Am J Clin Pathol 2001; 116:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/30\">",
"      Karanjia ND, Stiles PJ. Cubital bursitis. J Bone Joint Surg Br 1988; 70:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/31\">",
"      Ehrlich GE. Antecubital cysts in rheumatoid arthritis--a corollary to popliteal (Baker's) cysts. J Bone Joint Surg Am 1972; 54:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41223/abstract/32\">",
"      Harrington AC, Mellette JR Jr. Hernias of the anterior tibialis muscle: case report and review of the literature. J Am Acad Dermatol 1990; 22:123.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7761 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-122.72.76.133-D6C6C51ACA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41223=[""].join("\n");
var outline_f40_16_41223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1122984\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GANGLIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NODULES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Xanthomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Polyfibromatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fibroblastic rheumatism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nodules associated with repetitive trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Silicone and other injectables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Epidermoid cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      AIDS-related Kaposi's sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sweet syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Rheumatic fever nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pseudorheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Tophi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Panniculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Atypical infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      APPROACH TO THE PATIENT WITH A NODULAR LESION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1122984\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7761\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7761|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/35/32318\" title=\"picture 1\">",
"      Ganglion on wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/60/26575\" title=\"picture 2\">",
"      Inflamed tophaceous gout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/15/1264\" title=\"picture 3\">",
"      Lupus panniculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7761|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/37/14941\" title=\"table 1A\">",
"      Diagnosis nodular masses I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/1/29724\" title=\"table 1B\">",
"      Diagnosis nodular masses II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/23/6524\" title=\"table 2\">",
"      Associations with E nodosum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35541?source=related_link\">",
"      Approach to dermatologic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=related_link\">",
"      Approach to the child with peripheral lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30744?source=related_link\">",
"      Causes of peripheral lymphadenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13130?source=related_link\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18136?source=related_link\">",
"      Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=related_link\">",
"      Panniculitis: Recognition and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/21/338?source=related_link\">",
"      Patient information: Ganglion cyst (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/7/29815?source=related_link\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40905?source=related_link\">",
"      Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_16_41224="Telithromycin: Drug information";
var content_f40_16_41224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Telithromycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/1/17429?source=see_link\">",
"    see \"Telithromycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ketek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ketek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F225077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Ketolide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F225059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Community-acquired pneumonia:",
"     </b>",
"     Oral: 800 mg once daily for 7-10 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F225070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tonsillitis/pharyngitis (unlabeled use; Canadian indication): Children &ge;13 years: Oral: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F225060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F225061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute, including dialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. product labeling: 600 mg once daily; when renal impairment is accompanied by hepatic impairment, reduce dosage to 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian product labeling: Reduce dose to 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Administer following dialysis",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F225062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment recommended, unless concurrent severe renal impairment is present.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ketek&reg;: 300 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10134273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ketek&reg;: 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088615.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088615.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F225035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F225034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of community-acquired pneumonia (mild-to-moderate) caused by susceptible strains of",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     (including multidrug-resistant isolates),",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     ,",
"     <i>",
"      Chlamydophila pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      Moraxella catarrhalis",
"     </i>",
"     , and",
"     <i>",
"      Mycoplasma pneumoniae",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8382664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Telithromycin may be confused with telavancin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F225075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Diarrhea (10% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 6%), dizziness (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (7% to 8%), vomiting (2% to 3%), loose stools (2%), dysgeusia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;0.2% to &lt;2%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue, insomnia, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, abdominal pain, anorexia, constipation, dyspepsia, flatulence, gastritis, gastroenteritis, GI upset, glossitis, stomatitis, watery stools, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal candidiasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Platelets increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, accommodation delayed, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Candidiasis, diaphoresis increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;0.2% (Limited to important or life-threatening): Acute repiratory failure, alkaline phosphatase increased, allergic reaction, anaphylaxis, angioedema, anxiety, arrhythmia, bilirubin increased, bradycardia, edema (facial), eosinophilia, erythema multiforme, flushing, hepatitis, hepatitis, hepatocellular injury (including necrosis), hypotension, jaundice, liver failure, loss of consciousness (may be vagal-related), muscle cramps, myasthenia gravis exacerbation (rare), palpitation, pancreatitis, paresthesia, pruritus, pseudomembranous colitis, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, syncope, torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F225038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to telithromycin, macrolide antibiotics, or any component of the formulation; myasthenia gravis; history of hepatitis and/or jaundice associated with telithromycin or other macrolide antibiotic use; concurrent use of colchicine (if patient has concomitant renal or hepatic impairment), cisapride, pimozide, lovastatin, or simvastatin",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F225022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval, leading to a risk of ventricular arrhythmias; closely-related antibiotics have been associated with malignant ventricular arrhythmias and torsade de pointes. Avoid in patients with prolongation of QTc interval due to congenital causes, history of long QT syndrome, uncorrected electrolyte disturbances (hypokalemia or hypomagnesemia), significant bradycardia (&lt;50 bpm), or concurrent therapy with QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs (eg, class Ia and class III antiarrhythmics). Avoid use in patients with a prior history of confirmed cardiogenic syncope or ventricular arrhythmias while receiving macrolide antibiotics or other QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Acute hepatic failure and severe liver injury, including hepatitis and hepatic necrosis (leading to some fatalities) have been reported, in some cases after only a few doses; if signs/symptoms of hepatitis or liver damage occur, discontinue therapy and initiate liver function tests.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea and pseudomembranous colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: May cause loss of consciousness (possibly vagal-related); caution patients that these events may interfere with ability to operate machinery or drive, and to use caution until effects are known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual disturbances: May cause severe visual disturbances (eg, changes in accommodation ability, diplopia, blurred vision).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis:",
"     <b>",
"      [U.S. Boxed Warning]: Life-threatening (including fatal) respiratory failure has occurred in patients with myasthenia gravis;",
"     </b>",
"     use in these patients is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) requires dosage adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;13 years of age per Canadian approved labeling and &lt;18 years of age per U.S. approved labeling.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F225071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Macrolide Antibiotics may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Macrolide Antibiotics may decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Vinca Alkaloids): Macrolide Antibiotics may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues.  Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Macrolide Antibiotics may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Macrolide Antibiotics may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.  Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Macrolide Antibiotics may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Macrolide Antibiotics may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Macrolide Antibiotics may decrease the metabolism of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Macrolide Antibiotics may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Macrolide Antibiotics may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Telithromycin. Telithromycin may increase the serum concentration of Cobicistat.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Macrolide Antibiotics may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Macrolide Antibiotics may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Macrolide Antibiotics may decrease the metabolism of Eletriptan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Macrolide Antibiotics may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Macrolide Antibiotics may enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Macrolide Antibiotics. Clarithromycin AUC is reduced and levels of the active metabolite (14-hydroxy-clarithromycin) are modestly increased. Management: For the treatment of",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex, consider changing to alternative agent, such as azithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Macrolide Antibiotics may decrease the metabolism of HMG-CoA Reductase Inhibitors.  Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Macrolide Antibiotics may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Macrolide Antibiotics may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: Macrolide Antibiotics may decrease the metabolism of Rifamycin Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifapentine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Macrolide Antibiotics may decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE; PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Macrolide Antibiotics may decrease the metabolism of Sirolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Telithromycin. Telithromycin may increase the serum concentration of Telaprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Macrolide Antibiotics may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: Telithromycin may enhance the hypotensive effect of Verapamil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zopiclone: Macrolide Antibiotics may increase the serum concentration of Zopiclone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3031222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Herb/Nutraceutical: St John&rsquo;s wort: May decrease the levels/effects of telithromycin.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F225041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because adverse effects were observed in some animal studies, telithromycin is classified pregnancy category C. There are no adequate and well-controlled studies of telithromycin in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F225066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6063784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if telithromycin is excreted in breast milk. The manufacturer recommends caution if using telithromycin in a breast-feeding woman.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F225042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F225040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ketek Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (20): $345.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (60): $1036.73",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2523637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests; signs/symptoms of liver failure (eg, jaundice, fatigue, malaise, anorexia, nausea, bilirubinemia, acholic stools, liver tenderness, hepatomegaly); visual acuity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F225043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Engtel (PK);",
"     </li>",
"     <li>",
"      Ketek (AR, AT, BE, BG, BR, CH, CN, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HN, IE, IL, IT, KP, MT, MX, NI, NL, NO, NZ, PA, PE, PL, PT, PY, SE, SG, SK, SV, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Levviax (AT, BE, BG, CZ, DE, DK, EE, ES, FI, FR, GB, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F225021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial protein synthesis by binding to two sites on the 50S ribosomal subunit. Telithromycin has also been demonstrated to alter secretion of IL-1alpha and TNF-alpha; the clinical significance of this immunomodulatory effect has not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F225037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 2.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60% to 70%; primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP3A4 (50%) and non-CYP-mediated pathways",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 57% (significant first-pass metabolism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (13% unchanged drug, remainder as metabolites); feces (7%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Araujo FG, Slifer TL, and Remington JS, &ldquo;Inhibition of Secretion of Interleukin-1alpha and Tumor Necrosis Factor Alpha by the Ketolide Antibiotic Telithromycin,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2002, 46(10):3327-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/16/41224/abstract-text/12234873/pubmed\" id=\"12234873\" target=\"_blank\">",
"        12234873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhargava V, Lenfant B, Perret C, et al, &ldquo;Lack of Effect of Food on the Bioavailability of a New Ketolide Antibacterial, Telithromycin,&rdquo;",
"      <i>",
"       Scand J Infect Dis",
"      </i>",
"      , 2002, 34(11):823-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/16/41224/abstract-text/12578152/pubmed\" id=\"12578152\" target=\"_blank\">",
"        12578152",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cantalloube C, Bhargava V, Sultan E, et al, &ldquo;Pharmacokinetics of the Ketolide Telithromycin After Single and Repeated Doses in Patients With Hepatic Impairment,&rdquo;",
"      <i>",
"       Int J Antimicrob Agents",
"      </i>",
"      , 2003, 22(2):112-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/16/41224/abstract-text/12927950/pubmed\" id=\"12927950\" target=\"_blank\">",
"        12927950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canton R, Morosini M, Enright MC, et al, &ldquo;Worldwide Incidence, Molecular Epidemiology and Mutations Implicated in Fluoroquinolone-Resistant",
"      <i>",
"       Streptococcus pneumoniae",
"      </i>",
"      : Data From the Global PROTEKT Surveillance Programme,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2003, 52(6):944-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/16/41224/abstract-text/14585861/pubmed\" id=\"14585861\" target=\"_blank\">",
"        14585861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carbon C, &ldquo;A Pooled Analysis of Telithromycin in the Treatment of Community-Acquired Respiratory Tract Infections in Adults,&rdquo;",
"      <i>",
"       Infection",
"      </i>",
"      , 2003, 31(5):308-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/16/41224/abstract-text/14556055/pubmed\" id=\"14556055\" target=\"_blank\">",
"        14556055",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clay KD, Hanson JS, Pope SD, et al, &ldquo;Brief Communication: Severe Hepatotoxicity of Telithromycin: Three Case Reports and Literature Review,&rdquo;",
"      <i>",
"       Ann Int Med",
"      </i>",
"      , 2006, 144(6):451-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/16/41224/abstract-text/16549861/pubmed\" id=\"16549861\" target=\"_blank\">",
"        16549861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Demolis JL, Vacheron F, Cardus S, et al, &ldquo;Effect of Single and Repeated Oral Doses of Telithromycin on Cardiac QT Interval in Healthy Subjects,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2003, 73(3):242-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/16/41224/abstract-text/12621389/pubmed\" id=\"12621389\" target=\"_blank\">",
"        12621389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perret C, Lenfant B, Weinling E, et al, &ldquo;Pharmacokinetics and Absolute Oral Bioavailability of an 800-mg Oral Dose of Telithromycin in Healthy Young and Elderly Volunteers,&rdquo;",
"      <i>",
"       Chemotherapy",
"      </i>",
"      , 2002, 48(5):217-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/16/41224/abstract-text/12476037/pubmed\" id=\"12476037\" target=\"_blank\">",
"        12476037",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nieman RB, Sharma K, Edelberg H, et al, &ldquo;Telithromycin and Myasthenia Gravis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 37(11):1579.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quinn J, Ruoff GE, and Ziter PS, &ldquo;Efficacy and Tolerability of 5-Day, Once-Daily Telithromycin Compared With 10-Day, Twice-Daily Clarithromycin for the Treatment of Group A Beta-Hemolytic Streptococcal Tonsillitis/Pharyngitis: A Multicenter, Randomized, Double-Blind, Parallel-Group Study,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2003, 25(2):422-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/16/41224/abstract-text/12749505/pubmed\" id=\"12749505\" target=\"_blank\">",
"        12749505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ubukata K, Iwata S, and Sunakawa K, &ldquo;",
"      <i>",
"       In vitro",
"      </i>",
"      Activities of New Ketolide, Telithromycin, and Eight Other Macrolide Antibiotics Against",
"      <i>",
"       Streptococcus pneumoniae",
"      </i>",
"      Having mefA and ermB Genes That Mediate Macrolide Resistance,&rdquo;",
"      <i>",
"       J Infect Chemother",
"      </i>",
"      , 2003, 9(3):221-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/16/41224/abstract-text/14513389/pubmed\" id=\"14513389\" target=\"_blank\">",
"        14513389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zervos MJ, Heyder AM, and Leroy B, &ldquo;Oral Telithromycin 800 mg Once Daily for 5 Days Versus Cefuroxime Axetil 500 mg Twice Daily for 10 Days in Adults With Acute Exacerbations of Chronic Bronchitis,&rdquo;",
"      <i>",
"       J Int Med Res",
"      </i>",
"      , 2003, 31(3):157-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/16/41224/abstract-text/12870368/pubmed\" id=\"12870368\" target=\"_blank\">",
"        12870368",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10188 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41224=[""].join("\n");
var outline_f40_16_41224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709063\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225055\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225056\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225077\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225059\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225070\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225060\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225061\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225062\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225032\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10134273\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225019\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874996\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225035\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225034\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8382664\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225075\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225038\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225022\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225071\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225027\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3031222\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225029\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225041\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225066\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063784\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225042\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225040\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523637\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225043\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225021\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225037\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10188\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10188|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/1/17429?source=related_link\">",
"      Telithromycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_16_41225="Overview of the treatment of chronic myeloid leukemia";
var content_f40_16_41225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of chronic myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/16/41225/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41225/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41225/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/16/41225/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41225/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/16/41225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/16/41225/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/16/41225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myeloid leukemia (CML, chronic myelocytic or chronic myelogenous leukemia) is classified as a myeloproliferative disorder, along with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (",
"    <a class=\"graphic graphic_figure graphicRef56283 \" href=\"mobipreview.htm?24/16/24835\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This group of diseases shares several distinct features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They are clonal disorders of hematopoiesis that arise in a hematopoietic stem or early progenitor cell.",
"     </li>",
"     <li>",
"      They are characterized by the dysregulated production of a particular lineage of mature myeloid cells with fairly normal differentiation.",
"     </li>",
"     <li>",
"      They exhibit a variable tendency to progress to acute leukemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CML is associated with the Philadelphia chromosome t(9;22)(q34;q11) resulting in a BCR-ABL fusion gene (",
"    <a class=\"graphic graphic_figure graphicRef62227 \" href=\"mobipreview.htm?16/20/16719\">",
"     figure 2",
"    </a>",
"    ). This genetic abnormality results in the formation of a unique gene product (BCR-ABL), which is a constitutively active tyrosine kinase. This deregulated tyrosine kinase is implicated in the development of CML and has become a primary target for the treatment of this disorder.",
"   </p>",
"   <p>",
"    An overview of the treatment of CML will be presented here. Details on the diagnosis and differential diagnosis of CML are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The specific treatment of various phases of CML and practical issues regarding the use of different treatments (ie, use of tyrosine kinase inhibitors, interferon, and hematopoietic cell transplantation) are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISEASE PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of CML is based upon the specific disease phase. There are three general disease phases:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic stable phase",
"     </li>",
"     <li>",
"      Accelerated phase",
"     </li>",
"     <li>",
"      Blast crisis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CML usually progresses from a relatively indolent disease (termed chronic stable phase), easily controlled with oral chemotherapy, to a more aggressive disorder (accelerated phase), during which time disease control is more difficult to achieve.",
"   </p>",
"   <p>",
"    Varying definitions have been applied to the accelerated phase (",
"    <a class=\"graphic graphic_table graphicRef60902 \" href=\"mobipreview.htm?21/53/22364\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/1\">",
"     1",
"    </a>",
"    ]. The most frequently used criteria, the WHO definition, defines accelerated phase as patients with CML who show one or more of the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      10 to 19 percent blasts in the peripheral blood or bone marrow",
"     </li>",
"     <li>",
"      Peripheral blood basophils &ge;20 percent",
"     </li>",
"     <li>",
"      Platelets",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL,",
"      </span>",
"      unrelated to therapy",
"     </li>",
"     <li>",
"      Platelets",
"      <span class=\"nowrap\">",
"       &gt;1,000,000/microL,",
"      </span>",
"      unresponsive to therapy",
"     </li>",
"     <li>",
"      Progressive splenomegaly and increasing white cell count, unresponsive to therapy",
"     </li>",
"     <li>",
"      Cytogenetic evolution (defined as the development of chromosomal abnormalities in addition to the Philadelphia chromosome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In virtually all patients treated with palliative chemotherapeutic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    ) and in some patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , the disease culminates in an acute leukemia, termed \"blast crisis.\" This phase, which is generally refractory to treatment, occurs approximately three to five years after the diagnosis of CML and 18 months after the onset of the accelerated phase. In some patients, the progression to blast crisis can occur without an obvious preceding accelerated phase. More information on defining disease phase can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The blastic phase is usually defined by the presence of one or more of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ge;20 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/2\">",
"       2",
"      </a>",
"      ] percent peripheral blood or &ge;30 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/3\">",
"       3",
"      </a>",
"      ] percent bone marrow blasts",
"     </li>",
"     <li>",
"      Large foci or clusters of blasts on the bone marrow biopsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence of extramedullary blastic infiltrates (eg, myeloid sarcoma, also known as granulocytic sarcoma or chloroma) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, previous definitions of blast crisis vary in the percentage of bone marrow blasts required. Early definitions used a cutoff of &ge;30 percent while more recent definitions use a value of &ge;20 percent. This is important to keep in mind when making historical comparisons between response rates to treatment in accelerated phase and blast crisis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment decisions for patients with CML are complex, due to the variety of available options, many of which are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Available treatment options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potential cure with allogeneic hematopoietic cell transplantation (HCT)",
"     </li>",
"     <li>",
"      Disease control without cure using tyrosine kinase inhibitors (TKIs)",
"     </li>",
"     <li>",
"      Palliative therapy with cytotoxic agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors influencing the choice of therapy include: the phase of CML; availability of a donor for HCT; patient age; the presence of medical co-morbidities affecting patient suitability for HCT; and, for patients in earlier phases of CML, the response to treatment with tyrosine kinase inhibitors (TKI)s.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment option that comes at the cost of increased potential toxicity and early mortality. This option may be considered in younger patients with stable disease who have a suitable donor. HCT is also a key component of the treatment of accelerated phase and blast crisis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33066?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Results obtained with HCT in CML are directly related to the phase of disease at the time of the transplant. In the past, before the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , HCT within the first year after diagnosis resulted in the best outcome among patients in chronic phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33066?source=see_link&amp;anchor=H17#H17\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\", section on 'Pretreatment with tyrosine kinase inhibitors or interferon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of issues must be addressed when transplantation is considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient eligibility for the procedure with consideration of patient age and medical comorbidities.",
"     </li>",
"     <li>",
"      Choice of donor: The donor may be an identical twin (syngeneic), other relative (eg, sibling, parent), or unrelated donor.",
"     </li>",
"     <li>",
"      Closeness of match: Related or unrelated donors may be fully HLA-matched, haploidentical, or mismatched.",
"     </li>",
"     <li>",
"      Method of hematopoietic cell collection: Stem cells can be collected from the bone marrow, peripheral blood, or cord blood.",
"     </li>",
"     <li>",
"      Preparative regimen: Myeloablative or nonmyeloablative regimens may be employed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33066?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tyrosine kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;First and second-generation oral tyrosine kinase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ) target the constitutively active tyrosine kinase implicated in the pathogenesis of CML. Although they do not cure the disease, these agents are able to achieve long-term control of CML in the majority of patients; thus, they have become the initial treatment of choice for almost all newly diagnosed patients with CML. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents were much more commonly used in CML prior to the advent of the TKIs. These include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , interferon alpha with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/13/13526?source=see_link\">",
"     omacetaxine",
"    </a>",
"    mepesuccinate (previously known as homoharringtonine) is a protein synthesis inhibitor that has demonstrated activity in patients with CML. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=see_link&amp;anchor=H24874435#H24874435\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Omacetaxine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    (20 to 40",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    adjusted up or down to the nearest pill) can be used to reduce white blood cell counts while awaiting confirmation of a suspected diagnosis of CML in a patient with significant leukocytosis (eg, &gt;100 x10",
"    <sup>",
"     9",
"    </sup>",
"    white",
"    <span class=\"nowrap\">",
"     cells/L)",
"    </span>",
"    or in patients with systemic symptoms or with symptomatic splenomegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/9\">",
"     9",
"    </a>",
"    ]. The dose can be adjusted downward as the WBC count decreases.",
"   </p>",
"   <p>",
"    Up to 90 percent of patients will have a hematologic remission, amelioration of symptoms, and reduction or elimination of splenomegaly with these agents. However, these are considered palliative therapy since they are not curative, do not prolong overall survival, and only rarely result in attainment of a cytogenetic response.",
"   </p>",
"   <p>",
"    With the advent of HCT and the oral TKIs, the use of chemotherapeutic agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interferon as primary treatment is now mostly of historic interest, although they can be of benefit to patients who are not transplantation candidates and are intolerant or refractory to treatment with TKIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27111?source=see_link\">",
"     \"Interferon alpha for the treatment of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of tyrosine kinase inhibitors (TKIs) has been one of the most exhilarating stories in modern medicine. With the elucidation of the molecular defect in CML came a more complete understanding of the molecular biological derangements associated with the disease, culminating in the development of oral drugs, which are highly effective in its treatment.",
"   </p>",
"   <p>",
"    TKIs are the initial treatment of choice for the majority of patients with CML. The first trials of TKIs in BCR-ABL-positive disease evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in patients refractory to or intolerant of interferon therapy, which had been the standard of care prior to the availability of imatinib. Subsequently, the randomized IRIS trial compared imatinib with interferon therapy in previously untreated patients in chronic phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/11\">",
"     11",
"    </a>",
"    ]. Imatinib produced significantly higher hematologic and cytogenetic response rates with deeper, more durable responses, and much less toxicity. No survival benefit has been demonstrated due to the large number of patients allowed to switch from interferon to imatinib. However, several",
"    <span class=\"nowrap\">",
"     historical/retrospective",
"    </span>",
"    comparisons have shown significantly better overall survival following treatment with imatinib than with interferon-containing regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Thus, imatinib was the first approved TKI.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    can be used to reduce white blood cell counts while awaiting confirmation of a suspected diagnosis of CML in a patient with significant leukocytosis (eg, &gt;100 x10",
"    <sup>",
"     9",
"    </sup>",
"    white",
"    <span class=\"nowrap\">",
"     cells/L)",
"    </span>",
"    or in patients with systemic symptoms or with symptomatic splenomegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Other agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronic phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    was the first approved TKI for patients with CML in chronic phase. Initial reports from randomized trials have demonstrated that more potent, second generation TKIs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ) produce faster and deeper responses than imatinib. Further follow-up is needed to confirm whether the substantial short term improvements seen with second generation TKIs will result in longer term benefits, such as improved survival. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are transplant candidates, careful follow-up of response is critically important to predict when other therapies such as alternative TKIs or transplantation should be considered. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Monitoring response'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One clinical problem has become whether to refer patients for transplantation who have a complete cytogenetic response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    or whether to continue imatinib in the hope that the responses will be durable. Data at seven years of follow-up show that the responses have been very durable, with rates of progression being lower in successive years and with very few relapses after three to four years of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Accelerated or blast phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for CML in accelerated (",
"    <a class=\"graphic graphic_table graphicRef60902 \" href=\"mobipreview.htm?21/53/22364\">",
"     table 1",
"    </a>",
"    ) or blast phase is dismal (particularly for patients previously treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ), as these phases tend to be relatively resistant to most forms of treatment. Responses are short-lived, although responding patients survive longer than non-responders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. There is a significant relapse rate in patients in blast crisis or accelerated phase even after successful treatment with imatinib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    and it is appropriate to consider transplantation in such individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27976?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7816?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As such, a reasonable plan is to initiate a search for a matched donor while attempting to return the patient to a second chronic phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/19\">",
"     19",
"    </a>",
"    ] with suitable candidates subsequently undergoing transplantation. Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in the post transplant setting has resulted in an apparent reduction in relapse risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33066?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MONITORING RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with chronic phase CML will have an excellent response to initial treatment with a TKI. Although most patients achieve their best response within the first year of treatment, some patients continue to deepen their response at more than five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/21\">",
"     21",
"    </a>",
"    ]. It remains critically important to carefully follow the patient's disease status on a regular basis, although the optimal method remains uncertain. Routine cytogenetic analysis of a bone marrow biopsy specimen has been the gold standard for evaluating response in CML. As most patients are now able to attain a complete cytogenetic response, more sensitive tools, such as fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR), both qualitative and quantitative, are gathering increased use and can be used with peripheral blood sampling reducing the need for bone marrow biopsies. There are three principal strategies to assess the response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematologic response, as assessed by the white blood cell count, differential, and platelet count.",
"     </li>",
"     <li>",
"      Cytogenetic response, as assessed by bone marrow biopsy. Conventional chromosomal cytogenetics or FISH (for patients with an inadequate number of metaphases) are used to evaluate the percentage of Philadelphia chromosome positive cells present in the bone marrow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Molecular response, as assessed by quantitative PCR (Q-PCR) of the peripheral blood. This technique is used to detect the presence or absence of malignant circulating cells that harbor the BCR-ABL gene (",
"      <a class=\"graphic graphic_figure graphicRef53569 \" href=\"mobipreview.htm?10/24/10639\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link\">",
"       \"Cytogenetic and molecular genetic diagnostic tools\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A retrospective analysis compared the use of bone marrow cytogenetics, bone marrow FISH, peripheral blood FISH, bone marrow Q-PCR, and Q-PCR of the peripheral blood to monitor 70 patients with CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/25\">",
"     25",
"    </a>",
"    ]. Paired specimens obtained at the same time point from the peripheral blood and bone marrow demonstrated high correlation rates between bone marrow FISH and peripheral blood FISH (r=0.95), peripheral blood Q-PCR and bone marrow Q-PCR (r=0.87), bone marrow cytogenetics and peripheral blood FISH (r=0.89), and between bone marrow cytogenetics and peripheral blood Q-PCR (r=0.82). These results suggest that evaluation of the peripheral blood with FISH or Q-PCR may be used to monitor response and relapse. Bone marrow cytogenetics should be done to confirm initial complete response to therapy and should be repeated when there are significant rises in the peripheral blood quantitative PCR. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Schedule of evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Response criteria",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19442899\">",
"    <span class=\"h3\">",
"     Responses defined",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following categories define hematologic and cytogenetic treatment response in CML (",
"    <a class=\"graphic graphic_table graphicRef52082 \" href=\"mobipreview.htm?3/56/3981\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/22,26\">",
"     22,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete hematologic response (CHR) &mdash; White blood cell count",
"      <span class=\"nowrap\">",
"       &lt;10,000/microL",
"      </span>",
"      with no immature granulocytes and &lt;5 percent basophils on differential; platelet count",
"      <span class=\"nowrap\">",
"       &lt;450,000/microL;",
"      </span>",
"      and spleen not palpable.",
"     </li>",
"     <li>",
"      Complete cytogenetic response (CCgR) &mdash; No Philadelphia chromosome positive cells.",
"     </li>",
"     <li>",
"      Partial cytogenetic response (PCgR) &mdash; 1 to 35 percent Philadelphia chromosome positive cells.",
"     </li>",
"     <li>",
"      Major cytogenetic response (MCgR) includes patients with complete and partial cytogenetic response (ie, zero to 35 percent Philadelphia chromosome positive cells).",
"     </li>",
"     <li>",
"      Minor cytogenetic response (mCgR) &mdash; 36 to 65 percent Philadelphia chromosome positive cells.",
"     </li>",
"     <li>",
"      Minimal cytogenetic response (minCgR) &mdash; 66 to 95 percent Philadelphia chromosome positive cells.",
"     </li>",
"     <li>",
"      No cytogenetic response (noCgR) &mdash; &gt;95 percent Philadelphia chromosome positive cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As newer therapies have deepened responses, there has been a move towards redefining molecular responses. Initial response criteria divided molecular response as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/22,26,27\">",
"     22,26,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major molecular response (MMolR) &mdash; Ratio of BCR-ABL transcript to housekeeping genes &le;0.1 percent (&ge;3 log reduction) on the international scale (IS).",
"     </li>",
"     <li>",
"      Complete molecular response (CMolR) &mdash; BCR-ABL transcript nondetectable and not quantifiable in an assay that has at least 4 to 5 log range of detection on two consecutive blood samples.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As Q-PCR assays have become increasingly sensitive, the CML community has shifted to define CMolR by the upper boundary of detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/28\">",
"     28",
"    </a>",
"    ]. Using this method, the terms CMR",
"    <sup>",
"     4",
"    </sup>",
"    , CMR",
"    <sup>",
"     4.5",
"    </sup>",
"    , and CMR",
"    <sup>",
"     5",
"    </sup>",
"    have been used to indicate levels of disease that display a ratio of BCR-ABL transcript to housekeeping genes of &le;0.01 percent (&ge;4 log reduction), &le;0.0032 percent (&ge;4.5 log reduction), and &le;0.001 percent (&ge;5 log reduction), respectively, on the international scale. However, available data suggest that the term &ldquo;complete&rdquo; molecular response is misleading and likely inaccurate in this setting since residual leukemia stem cells may be found in patients who achieve these levels of disease control. As such, it has been proposed that the term &ldquo;complete&rdquo; be abandoned and that molecular response (MR) be defined according to the level of detection of the assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MMolR (MR",
"      <sup>",
"       3",
"      </sup>",
"      ) &mdash; Detectable disease &le;0.1 percent (&ge;3 log reduction) on the IS.",
"     </li>",
"     <li>",
"      MR",
"      <sup>",
"       4",
"      </sup>",
"      &mdash; Either detectable disease &le;0.01 percent (&ge;4 log reduction) on the IS or undetectable disease in cDNA with &ge;10,000 ABL transcripts. This definition implies that the assay being used is sensitive enough to detect a single abnormal transcript amongst 10,000 normal ABL transcripts.",
"     </li>",
"     <li>",
"      MR",
"      <sup>",
"       4.5",
"      </sup>",
"      &mdash; Either detectable disease &le;0.0032 percent (&ge;4.4 log reduction) on the IS or undetectable disease in cDNA with &ge;32,000 ABL transcripts. This definition implies that the assay being used is sensitive enough to detect a single abnormal transcript amongst 32,000 normal ABL transcripts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At this time, it is unknown whether patients with lower or undetectable transcript levels have a better long term outcome since the relapse rate is very low in patients with sustained MR",
"    <sup>",
"     3",
"    </sup>",
"    or indeed those with complete cytogenetic response without MR",
"    <sup>",
"     3",
"    </sup>",
"    . Future trials may help determine whether discontinuation of therapy may be more successful in those with lower or undetectable transcript levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19442906\">",
"    <span class=\"h3\">",
"     Defining failure, suboptimal response, and optimal response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The European LeukemiaNet has developed criteria for the definitions of treatment failure and for suboptimal and optimal response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment failure is defined by the loss of a complete hematologic response or complete cytogenetic response; the presence of BCR-ABL kinase mutations that are poorly sensitive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ; clonal progression of disease; or the inability to reach the following threshold levels after the initiation of therapy (",
"    <a class=\"graphic graphic_table graphicRef81376 \" href=\"mobipreview.htm?3/44/3789\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/26,29\">",
"     26,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete hematologic response by three months",
"     </li>",
"     <li>",
"      Any cytogenetic response by six months",
"     </li>",
"     <li>",
"      Partial cytogenetic response by 12 months",
"     </li>",
"     <li>",
"      Complete cytogenetic response by 18 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A suboptimal response occurs when there is (",
"    <a class=\"graphic graphic_table graphicRef81376 \" href=\"mobipreview.htm?3/44/3789\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No complete hematologic or cytogenetic response by three months",
"     </li>",
"     <li>",
"      Less than a partial cytogenetic response by six months",
"     </li>",
"     <li>",
"      Less than a complete cytogenetic response by 12 months",
"     </li>",
"     <li>",
"      Less than a major molecular response by 18 months",
"     </li>",
"     <li>",
"      Loss of major molecular response at any time during treatment",
"     </li>",
"     <li>",
"      Identification of BCR-ABL kinase mutations that are poorly sensitive to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An optimal response is defined as (",
"    <a class=\"graphic graphic_table graphicRef81376 \" href=\"mobipreview.htm?3/44/3789\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete hematologic response and at least minor cytogenetic response by three months",
"     </li>",
"     <li>",
"      At least partial cytogenetic response by six months",
"     </li>",
"     <li>",
"      Complete cytogenetic response by twelve months",
"     </li>",
"     <li>",
"      Major molecular response by 18 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These definitions of treatment failure, suboptimal response, and optimal response were developed for patients in chronic phase CML undergoing treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/26\">",
"     26",
"    </a>",
"    ]. The same definitions may be used in patients in chronic phase CML receiving a second generation TKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], although some groups have suggested the use of more stringent criteria in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/32\">",
"     32",
"    </a>",
"    ]. These response definitions will change with the evolution of treatment options, and are in the process of being updated. It is easier to define treatment failure and suboptimal response and more difficult to define an optimal response with regard to progression-free and overall survival. Nevertheless, these consensus definitions of response help guide therapy and also allow for better comparison of trials. Most progression events occur within the first two to three years after stating TKI therapy for chronic phase CML. Thus, an earlier, deeper response may provide an additional clinical benefit.",
"   </p>",
"   <p>",
"    Support for the use of these response criteria comes from retrospective and prospective studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of 224 patients found that treatment failure, as defined above, was associated with significantly lower rates of overall and progression-free survival when compared with patients who achieved the treatment goals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/33\">",
"       33",
"      </a>",
"      ]. In addition, patients with a suboptimal response had lower rates of progression-free survival at 6 and 12 months.",
"     </li>",
"     <li>",
"      A second study of 281 patients with CML in chronic phase reported suboptimal response rates at 6, 12, and 18 months of 4, 8, and 40 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/34\">",
"       34",
"      </a>",
"      ]. When compared with patients achieving an optimal response, the four-year event-free survival rates were significantly inferior for those who had a suboptimal response at 6 months (45 versus 93 percent); trending towards inferiority for those with a suboptimal response at 12 months (87 versus 96 percent); and similar for those who had a suboptimal response at 18 months (approximately 95 percent each). Thus, the importance of attaining a molecular response at 18 months is unclear.",
"     </li>",
"     <li>",
"      A landmark analysis of 435 patients with CML in chronic phase reported superior three-year event-free survival rates in patients who achieved a complete cytogenetic response (CCyR) at three months (98 versus 83 percent), six months (97 versus 72 percent), and 12 months (98 versus 67 percent) when compared with patients who did not achieve a CCyR at that time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/35\">",
"       35",
"      </a>",
"      ]. Three-year overall survival was also improved in patients who achieved a CCyR at three months (99 versus 95 percent), six months (99 versus 90 percent), and 12 months (99 versus 94 percent). The depth of molecular response was not associated with these clinical outcomes.",
"     </li>",
"     <li>",
"      An unplanned analysis of a subset of patients from the IRIS trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      as front-line therapy for CML found that no patients who achieved an MMR by 18 months progressed to accelerated phase or blast crisis by seven years and that the event-free survival rate for this population was 95 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/36\">",
"       36",
"      </a>",
"      ]. In comparison, patients who achieved a complete cytogenetic response but not MMR were more likely to lose CCR by seven years (26 versus 3 percent).",
"     </li>",
"     <li>",
"      A single-institution study of 282 patients with CML in chronic phase initially treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and followed for a median of 69 months used receiver operating characteristics (ROC) curves to determine optimal cutoff values of BCR-ABL to c-ABL transcript ratios to use at three, six, and 12 months to predict the probability of overall and progression-free survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/37\">",
"       37",
"      </a>",
"      ]. Using the International Scale, ratios of &le;9.84 percent at three months, &le;1.67 percent at six months, and &le;0.53 percent at 12 months were associated with superior survival. For those clinicians who do not have access to laboratories using the International Scale, these molecular ratios correspond approximately to a hematologic response, major cytogenetic response and complete cytogenetic response respectively. These results suggest that rapid early responses have long-term benefit in this population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most circumstances, changes in molecular findings alone should not be used to alter therapy in individual patients. In particular, changes in a single PCR result should NOT prompt changes in treatment, because of variability in the reproducibility of the assay in some laboratories. In contrast, a pattern of increasing PCR signal over time is a more important finding, suggesting the possibility of relapse and a need for closer monitoring and BCR-ABL mutational analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all patients with a rising PCR signal will develop clinical relapse. In one study, for example, only 11 (9.5 percent) of 116 patients in complete cytogenetic response on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy who demonstrated a rising PCR signal on at least two occasions developed progressive disease as defined by the loss of cytogenetic or hematologic response or the development of accelerated or blast phase disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/41\">",
"     41",
"    </a>",
"    ]. Furthermore, it has not been shown that earlier intervention with imatinib dose increase or a switch to a second generation TKI is of benefit to patients with molecular progression only.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Schedule of evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differences in laboratory technique and control genes make it difficult to compare PCR values among laboratories. While initial efforts to create an international standardized scale for quantitative PCR for BCR-ABL measurements look promising, it is preferable to obtain serial samples from individual patients at the same laboratory, if possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of monitoring schedules for patients with CML are acceptable. One approach to monitoring disease in patients in chronic phase is the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After a patient is diagnosed with chronic phase CML, monitor complete blood counts with differential every one to two weeks until these counts are stable.",
"     </li>",
"     <li>",
"      If the patient achieves a complete hematologic response and the counts are stable, perform complete blood counts, chemistries, and quantitative RT-PCR or FISH on the peripheral blood every three months. Bone marrow cytogenetics are performed when the peripheral blood FISH is zero to 5 percent positive or the RT-PCR is at a value which in your laboratory corresponds to a complete cytogenetic response.",
"     </li>",
"     <li>",
"      If the patient achieves a complete cytogenetic response, the following is performed every three to four months: complete blood count with differential and quantitative RT-PCR, if available, on the peripheral blood. If the Q-PCR assay is not available, then FISH on peripheral blood cells can be used to monitor for evidence of progression. Bone marrow cytogenetics should be repeated when there are significant rises in the peripheral blood quantitative PCR. Some centers advocate bone marrow cytogenetics every 18 to 24 months for patients in complete cytogenetic response to evaluate for the presence of clonal abnormalities in Philadelphia chromosome negative cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/43\">",
"       43",
"      </a>",
"      ]. However, most often these abnormal clones remain small and clinically insignificant. If molecular tests (Q-PCR or FISH) on peripheral blood cells remain negative for the",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      fusion gene and blood counts are normal, there is little to be learned from sequential bone marrow examinations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Evaluation at loss of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;When there is evidence for a loss of response to therapy, the disease phase should be re-evaluated with a bone marrow biopsy with cytogenetics. In addition, patients with either an inadequate response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    or in whom there is a loss of response, BCR-ABL kinase mutational analysis is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/39\">",
"     39",
"    </a>",
"    ]. A newly acquired mutation in BCR-ABL may trigger a change in treatment (eg, dose increase, change to another TKI, HCT) depending upon the type of mutation found.",
"   </p>",
"   <p>",
"    Mutational analysis of BCR-ABL is recommended for all patients who fail to respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/39,44\">",
"     39,44",
"    </a>",
"    ]. This is most commonly performed using conventional direct sequencing of the kinase domain. While more sensitive methods of detecting mutations have been described, the clinical impact of low levels of mutant BCR-ABL is not yet known.",
"   </p>",
"   <p>",
"    Although clinical data describing the relative benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    in patients with different mutations are now being analyzed, these data may help guide the choice of therapy in the future [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/44\">",
"     44",
"    </a>",
"    ]. Notable examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The T315I mutation has shown resistance to all currently available TKIs with the exception of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      . If such patients are treated with ponatinib, they should be evaluated simultaneously for allogeneic transplantation. If ponatinib therapy is not successful, use of an investigational agent as part of a clinical trial can be considered.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/13/13526?source=see_link\">",
"       Omacetaxine",
"      </a>",
"      has also demonstrated activity in some patients with the T315I mutation.",
"     </li>",
"     <li>",
"      The Y253H,",
"      <span class=\"nowrap\">",
"       E255K/V,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       F359V/C/I",
"      </span>",
"      mutations are resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      but sensitive to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       F317L/V/I/C,",
"      </span>",
"      V299L, and T315A mutations are sensitive to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      but shows intermediate sensitivity to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At this time, the choice of a second generation TKI for most patients is dependent upon drug side effect profile and patient co-morbidities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT OF DISEASE RESISTANCE OR DRUG INTOLERANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small proportion of previously untreated patients with chronic phase CML are resistant to (5 percent) or intolerant of (3 percent) treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, many patients with initial responses to imatinib ultimately lose their response. At 18 months to two years, resistance is observed in 80, 40 to 50, and 10 to 15 percent of patients initially in blast crisis, accelerated phase, or chronic phase, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27976?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7816?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such relapses are associated with a poorer overall prognosis, despite subsequent treatment with other TKIs or HCT. As an example, in a retrospective analysis from the M.D. Anderson Cancer Center, estimated three-year survival rates for patients failing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy in blast, accelerated, or chronic phase were 7, 30, and 72 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The newer TKIs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    were initially evaluated in patients in whom",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy had failed, either due to relapse of disease or drug intolerance. Most, but not all, patients in these circumstances will respond to these newer agents as shown in phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trials. Based on these trials, dasatinib, nilotinib, bosutinib, and ponatinib are approved for the treatment of chronic or accelerated phase CML with resistance or intolerance to prior therapy with a TKI. Dasatinib is also approved for the treatment of blast phase CML with resistance or intolerance to prior imatinib. As experience with the newer TKIs has matured, the use of chemotherapy in patients resistant to or intolerant of imatinib has declined. However, it can be explored, in the context of a clinical trial, in subjects with the T315I mutation of BCR-ABL who do not respond to therapy with ponatinib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following options are currently available for the patient who has become intolerant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    or shows excessive toxicity, treatment failure, or a suboptimal response to imatinib (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Monitoring response'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of increased doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      if the patient is still able to tolerate this agent.",
"     </li>",
"     <li>",
"      Use of an alternative tyrosine kinase inhibitor. The choice of agent may depend upon drug side effects, patient co-morbidities, and possibly, as described above, the particular type of BCR-ABL mutation. Of note, however, mutations are not detectable in a percentage of patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      resistant CML, indicating the importance of other, as yet poorly characterized mechanisms of resistance. Clinical conditions in an individual patient (eg, history of heart failure) might also be indicative of more toxicity with one of these agents.",
"     </li>",
"     <li>",
"      Allogeneic hematopoietic cell transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33066?source=see_link\">",
"       \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These options are not mutually exclusive, and results of large phase III randomized trials to determine the optimal strategy among competing options are not yet available. However, results from a randomized phase II trial demonstrated superior outcomes with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    in this setting when compared with increased doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/16/41225/abstract/53\">",
"     53",
"    </a>",
"    ]. Accordingly, the benefits, risks, and side effects of these treatment options should be discussed with the patient in some detail before a treatment decision is made.",
"   </p>",
"   <p>",
"    The specific treatment of patients with disease resistant to initial therapy or who are intolerant to initial therapy is also discussed in other sections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27976?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7816?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/58/12194?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/60/37829?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with chronic myeloid leukemia (CML) can present in one of three general disease phases: chronic phase, accelerated phase, or blast crisis. In addition, patients can progress from one to the other as their disease responds or does not respond to treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Disease phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options for patients with CML are varied and include: potential cure with allogeneic hematopoietic cell transplantation (HCT); disease control without cure using tyrosine kinase inhibitors (TKIs); or palliative therapy with cytotoxic agents. Factors influencing the choice of therapy include: the phase of CML; availability of a donor for HCT; patient age; the presence of medical co-morbidities affecting patient suitability for HCT; and, for patients in earlier phases of CML, the response to treatment with tyrosine kinase inhibitors (TKIs). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview of treatment options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TKIs are the initial treatment of choice for most patients with chronic phase CML. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chronic phase'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7034?source=see_link\">",
"       \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CML in accelerated phase or blast crisis is much more difficult to control. Although many patients will have an initial response to tyrosine kinase inhibitor (TKI) therapy, such responses are often short-lived. As such, a reasonable plan is an attempt to return the patient to a second chronic phase using a TKI with suitable candidates subsequently undergoing allogeneic hematopoietic cell transplantation (HCT). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Accelerated or blast phase'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27976?source=see_link\">",
"       \"Treatment of chronic myeloid leukemia in accelerated phase\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7816?source=see_link\">",
"       \"Treatment of chronic myeloid leukemia in blast crisis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33066?source=see_link\">",
"       \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Monitoring of residual disease is an important component of treatment of patients with CML, although the optimal method remains uncertain. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Monitoring response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A small proportion of previously untreated patients with chronic phase CML are resistant to (5 percent) or intolerant of (3 percent) treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      . In addition, many patients with initial responses to imatinib ultimately lose their response. Treatment options for such patients include second generation TKIs, HCT, or increased dose imatinib (in patients still able to tolerate this agent). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment of disease resistance or drug intolerance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=see_link\">",
"       \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27976?source=see_link\">",
"       \"Treatment of chronic myeloid leukemia in accelerated phase\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7816?source=see_link\">",
"       \"Treatment of chronic myeloid leukemia in blast crisis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/1\">",
"      Cortes JE, Talpaz M, O'Brien S, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 2006; 106:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/2\">",
"      Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/3\">",
"      Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/4\">",
"      Kantarjian HM, O'Brien S, Cortes J, et al. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003; 98:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/5\">",
"      Lee SJ. Chronic myelogenous leukaemia. Br J Haematol 2000; 111:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/6\">",
"      Kantarjian HM, Cortes J, Guilhot F, et al. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer 2007; 109:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/7\">",
"      Biggs JC, Szer J, Crilley P, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992; 80:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/8\">",
"      Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84:4064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/9\">",
"      Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood 2012; 120:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/10\">",
"      Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Chronic myeloid leukemia trialists' collaborative group. Br J Haematol 2000; 110:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/11\">",
"      O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/12\">",
"      Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006; 108:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/13\">",
"      Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006; 108:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/14\">",
"      Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012; 119:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/15\">",
"      Bauduer F, Delmer A, Blanc MC, et al. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine. Leuk Lymphoma 1993; 10:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/16\">",
"      Kouides PA, Rowe JM. A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis. Leuk Res 1995; 19:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/17\">",
"      Barone S, Baer MR, Sait SN, et al. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis. Am J Hematol 2001; 67:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/18\">",
"      Oki Y, Kantarjian HM, Gharibyan V, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007; 109:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/19\">",
"      Lange T, G&uuml;nther C, K&ouml;hler T, et al. High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 2003; 101:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/20\">",
"      Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/21\">",
"      Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008; 111:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/22\">",
"      Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008; 111:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/23\">",
"      Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007; 357:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/24\">",
"      Testoni N, Marzocchi G, Luatti S, et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009; 114:4939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/25\">",
"      Lima L, Bernal-Mizrachi L, Saxe D, et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer 2011; 117:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/26\">",
"      Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27:6041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/27\">",
"      Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/28\">",
"      Cross NC, White HE, M&uuml;ller MC, et al. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/29\">",
"      Guilhot J, Baccarani M, Clark RE, et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood 2012; 119:5963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/30\">",
"      Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008; 112:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/31\">",
"      Hochhaus A, M&uuml;ller MC, Radich J, et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 2009; 23:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/32\">",
"      Jabbour E, Kantarjian HM, O'Brien S, et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol 2011; 29:4260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/33\">",
"      Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112:4437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/34\">",
"      Alvarado Y, Kantarjian H, O'Brien S, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009; 115:3709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/35\">",
"      Jabbour E, Kantarjian H, O'Brien S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011; 118:4541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/36\">",
"      Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010; 116:3758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/37\">",
"      Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/38\">",
"      Marin D, Khorashad JS, Foroni L, et al. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol 2009; 145:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/39\">",
"      Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/40\">",
"      Branford S, Yeung DT, Prime JA, et al. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood 2012; 119:4264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/41\">",
"      Kantarjian HM, Shan J, Jones D, et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 2009; 27:3659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/42\">",
"      Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112:3330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/43\">",
"      Cortes J, Quint&aacute;s-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer 2011; 117:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/44\">",
"      O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/45\">",
"      O'Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004; 103:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/46\">",
"      Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/47\">",
"      Kantarjian H, Talpaz M, O'Brien S, et al. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003; 97:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/48\">",
"      Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23:4100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/49\">",
"      Kantarjian H, O'Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007; 109:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/50\">",
"      de Lavallade H, Khorashad JS, Davis HP, et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 2007; 110:2779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/51\">",
"      Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006; 108:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/52\">",
"      Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/16/41225/abstract/53\">",
"      Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109:5143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4496 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41225=[""].join("\n");
var outline_f40_16_41225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISEASE PHASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tyrosine kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronic phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Accelerated or blast phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MONITORING RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Response criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19442899\">",
"      - Responses defined",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19442906\">",
"      - Defining failure, suboptimal response, and optimal response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Schedule of evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Evaluation at loss of response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT OF DISEASE RESISTANCE OR DRUG INTOLERANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4496\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4496|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/16/24835\" title=\"figure 1\">",
"      Organiz heme malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/20/16719\" title=\"figure 2\">",
"      The Philadelphia chromosome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/24/10639\" title=\"figure 3\">",
"      BCR ABL ratio leukemic cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4496|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/53/22364\" title=\"table 1\">",
"      Accel phase CML criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/56/3981\" title=\"table 2\">",
"      Response definitions CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/44/3789\" title=\"table 3\">",
"      CML treatment milestones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33066?source=related_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7034?source=related_link\">",
"      Initial treatment of chronic myeloid leukemia in chronic phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27111?source=related_link\">",
"      Interferon alpha for the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/58/12194?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27976?source=related_link\">",
"      Treatment of chronic myeloid leukemia in accelerated phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7816?source=related_link\">",
"      Treatment of chronic myeloid leukemia in blast crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_16_41226="MEG - magnetoencephalography recording";
var content_f40_16_41226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 597px\">",
"   <div class=\"ttl\">",
"    Simultaneous magnetoencephalography (MEG) and electroencephalography (EEG) recordings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 577px; height: 515px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneous MEG (black) and EEG (green) recordings: Three sample clips on the MEG showing typical spike discharges (red boxes). Note the high frequency activity in the right frontal quadrant preceding the spike on the left, and the bisynchronous spike on the far right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Catherine Schevon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41226=[""].join("\n");
var outline_f40_16_41226=null;
var title_f40_16_41227="Therapeutic lifestyle diet";
var content_f40_16_41227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nutrient composition of the therapeutic lifestyle changes diet",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nutrient",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Saturated fat*",
"       </td>",
"       <td>",
"        &lt;7 percent&nbsp;of total calories",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyunsaturated fat",
"       </td>",
"       <td>",
"        Up to 10 percent&nbsp;of total calories",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monounsaturated fat",
"       </td>",
"       <td>",
"        Up to 20 percent&nbsp;of total calories",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total fat",
"       </td>",
"       <td>",
"        25 to 35 percent&nbsp;of total calories",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbohydrate&bull;",
"       </td>",
"       <td>",
"        50 to 60 percent&nbsp;of total calories",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fiber",
"       </td>",
"       <td>",
"        20 to 30 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein",
"       </td>",
"       <td>",
"        Approximately 15 percent&nbsp;of total calories",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholesterol",
"       </td>",
"       <td>",
"        &lt;200 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total calories&Delta;",
"       </td>",
"       <td>",
"        Balance energy intake and expenditure to maintain desirable body weight and prevent weight gain",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Trans fatty acids are another LDL-raising fat that should be kept at low intake.",
"     <br>",
"      &bull; Carbohydrates should be derived predominantly from foods rich in complex carbohydrates including grains, especially whole grains, fruits, and vegetables.",
"      <br>",
"       &Delta; Daily energy expenditure should include at least moderate physical activity (contributing approximately 200 kcal/day).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Adult Treatment Panel III at file://www.nhlbi.nih.gov/.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41227=[""].join("\n");
var outline_f40_16_41227=null;
var title_f40_16_41228="Recurrent post XRT thyroid cancer";
var content_f40_16_41228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ten-year local recurrence rates after adjuvant external radiation therapy for high-risk disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Study",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Treatment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Surgery with radioactive iodine (percent)",
"      </td>",
"      <td class=\"subtitle2\">",
"       Surgery, radioactive iodine, and radiation therapy (percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tubiana et al [9]",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       14",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Simpson et al [7]",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       14",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phlips et al [6]",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Farahati et al (includes distant failures) [3]",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tsang et al (papillary only) [8]",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kim et al (papillary only, 5 year rates) [5]",
"      </td>",
"      <td>",
"       37.5",
"      </td>",
"      <td>",
"       4.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Keum et al [4]",
"      </td>",
"      <td>",
"       89",
"      </td>",
"      <td>",
"       38",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Brierley et al (patients over 60 with ETE) [1]",
"      </td>",
"      <td>",
"       34.3",
"      </td>",
"      <td>",
"       13.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chow et al (papillary only with T4a) [2]",
"      </td>",
"      <td>",
"       17.6",
"      </td>",
"      <td>",
"       11.6",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     1. Brierley JD, Tsang RW, Gospodarowicz MK, et al. Medullary thyroid cancer - analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996; 6:305.",
"     <br>",
"      2. Chow SM, Law SCK, Mendenhall WM, et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52:784.",
"      <br>",
"       3. Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 1996; 77:172.",
"       <br>",
"        4. Keum KC, Suh YG, Koom WS, et al. The role of postoperative external-beam radiotherapy in the management of patients with papillary thyroid cancer invading the trachea. Int J Radiat Oncol Biol Phys 2006; 65:474.",
"        <br>",
"         5. Kim TH, Yang DS, Jung KY, et al. Value of external irradiation for locally advanced papillary thyroid cancer. In J Radiat Oncol Biol Phys 2003; 55:1006.",
"         <br>",
"          6. Phlips P, Hanzen C, Andry G, et al. Postoperative irradiation for thyroid cancer. Clin Oncol (R Coll Radiol) 2004; 16:561.",
"          <br>",
"           7. Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1998; 14:1063.",
"           <br>",
"            8. Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine and external radiation therapy on the clinical outcome of patients with differentiated thyroid cancer. Cancer 1998; 82:375.",
"            <br>",
"             9. Tubiana M, Haddad E, Schlumberger M, et al. External radiotherapy in thyroid cancers. Cancer 1985; 55:2062.",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Brierley JD, Tsang R. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am 2008; 37:497. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41228=[""].join("\n");
var outline_f40_16_41228=null;
var title_f40_16_41229="Pharmacologic treatment of high altitude illness";
var content_f40_16_41229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacologic treatment of high altitude illness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preferred agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        <strong>",
"         AMS/HACE",
"        </strong>",
"       </td>",
"       <td>",
"        Prevention*",
"       </td>",
"       <td>",
"        <strong>",
"         Acetazolamide:",
"        </strong>",
"        125 mg PO every 12 hrs",
"        <br/>",
"        <p>",
"         Children: 2.5 mg/kg (maximum single dose: 125 mg) PO every 12 hrs",
"        </p>",
"        <p>",
"         Duration: start day before ascent and continue 2-3 days at maximum altitude; may use once at night thereafter to improve sleep",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Dexamethasone:",
"        </strong>",
"        2 mg PO every 6 hrs or 4 mg PO every 12 hrs",
"        <br/>",
"        <p>",
"         Children: Acetazolamide preferred, do not use for prophylaxis",
"        </p>",
"        <p>",
"         Duration: start day of ascent and continue 2-3 days at maximum altitude, but for no more than 7 days total",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment mild AMS",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <strong>",
"         Acetazolamide:",
"        </strong>",
"        125 to 250 mg PO every 12 hours",
"        <br/>",
"        <p>",
"         Children: 2.5 mg/kg (maximum single dose: 250 mg) PO every 12 hours",
"        </p>",
"        <p>",
"         Duration: continue for 24 hrs after symptoms resolve or descent accomplished",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Dexamethasone:",
"        </strong>",
"        2 to 4 mg PO every 6 hrs",
"        <br/>",
"        <p>",
"         Children: 0.15 mg/kg PO every 6 hrs (maximum single dose: 4 mg)",
"        </p>",
"        <p>",
"         Duration: continue until 24 hrs after symptoms resolve or descent completed, but not longer than 7 days total",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment moderate to severe AMS",
"       </td>",
"       <td>",
"        <strong>",
"         Dexamethasone:",
"        </strong>",
"        4 mg PO every 6 hrs",
"        <br/>",
"        <p>",
"         Children: 0.15 mg/kg PO (maximum single dose: 4 mg) every 6 hrs",
"        </p>",
"        <p>",
"         Duration: continue until 24 hrs after symptoms resolve or descent completed, but not longer than 7 days total",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Acetazolamide:",
"        </strong>",
"        125 to 250 mg PO every 12 hours",
"        <br/>",
"        <p>",
"         Children: 2.5 mg/kg (maximum single dose: 250 mg) PO every 12 hours",
"        </p>",
"        <p>",
"         Duration: continue for 24 hrs after symptoms resolve or descent accomplished",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HACE treatment",
"       </td>",
"       <td>",
"        <strong>",
"         Dexamethasone:",
"        </strong>",
"        8 mg PO/IM/IV once, then 4 mg PO/IM/IV every 6 hours",
"        <br/>",
"        <p>",
"         Children: 0.15 mg/kg every 6 hours (maximum single dose: 4 mg)",
"        </p>",
"        <p>",
"         Duration: continue until 24 hrs after symptoms resolve or descent completed, but not longer than 7 days total",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Acetazolamide:",
"        </strong>",
"        250 mg PO every 12 hours, may use as adjunct with dexamethasone; NOT for monotherapy",
"        <br/>",
"        <p>",
"         Children: 2.5 mg/kg (maximum single dose: 250 mg) PO every 12 hours",
"        </p>",
"        <p>",
"         Duration: continue until 24 hrs after symptoms resolve or descent accomplished",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         HAPE",
"        </strong>",
"       </td>",
"       <td>",
"        HAPE prevention*",
"       </td>",
"       <td>",
"        <strong>",
"         Nifedipine:",
"        </strong>",
"        60 mg extended-release PO divided daily (30 mg PO every 12 hrs; or 20 mg PO every 8 hrs)",
"        <br/>",
"        <p>",
"         Children: 0.5 mg/kg (maximum single dose: 20 mg) extended-release PO every 8 hrs",
"        </p>",
"        <p>",
"         Duration: start day before ascent and continue for 3-5 days at max altitude",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Further research is needed before the medications listed below can be recommended for routine use:",
"        </p>",
"        <p>",
"         <strong>",
"          Tadalafil:",
"         </strong>",
"         10 mg PO every 12 hrs; start day of ascent and continue 3-5 days at maximum altitude",
"        </p>",
"        <p>",
"         <strong>",
"          Sildenafil:",
"         </strong>",
"         50 mg PO every 8 hours; start day of ascent and continue 3-5 days at maximum altitude",
"        </p>",
"        <p>",
"         <strong>",
"          Dexamethasone:",
"         </strong>",
"         8 mg PO every 12 hours; start day of ascent and continue 48-72 hours at maximum altitude",
"        </p>",
"        <p>",
"         <strong>",
"          Acetazolamide:",
"         </strong>",
"         125-250 mg PO every 12 hours; start day before ascent and continue 48-72 hours at maximum altitude",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HAPE treatment",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <strong>",
"         Nifedipine:",
"        </strong>",
"        60 mg extended-release PO divided daily (30 mg PO every 12 hrs; or 20 mg PO every 8 hrs)",
"        <br/>",
"        <p>",
"         Children: 0.5 mg/kg (maximum single dose: 20 mg) extended-release PO every 8 hrs",
"        </p>",
"        <p>",
"         Duration: continue until descent completed, symptoms resolved and SpO2 normal for altitude",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Further research is needed before the medications listed below can be recommended for routine use in HAPE treatment:",
"        </p>",
"        <p>",
"         <strong>",
"          Tadalafil:",
"         </strong>",
"         10 mg PO every 12 hours",
"        </p>",
"        <p>",
"         <strong>",
"          Sildenafil:",
"         </strong>",
"         50 mg PO every 8 hrs",
"        </p>",
"        <p>",
"         Duration: continue until descent completed, symptoms resolved and SpO2 normal for altitude",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * See text. Gradual ascent profile is primary method of prevention. Reserve pharmacologic prophylaxis for mod to high-risk scenarios.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     See text. May not require any pharmacologic intervention. Rest, halt ascent, and symptomatic treatment may be sufficient.",
"     <br/>",
"     &Delta; See text. May not require any pharmacologic intervention. In proper setting, rest and supplemental oxygen may be sufficient.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Luks A, McIntosh S, Grissom CK, et al. Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness. Wilderness Environ Med 2010; 21:146.",
"      </li>",
"      <li>",
"       Pollard A, Niermeyer S, Barry P, et al. Children at High Altitude: An International Consensus, Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001. High Altitude Medicine &amp; Biology. Volume 2, Number 3, 2001. Mary Ann Liebert, Inc. Pages 389-403.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41229=[""].join("\n");
var outline_f40_16_41229=null;
var title_f40_16_41230="TEE prosthetic mitral valve vegetation";
var content_f40_16_41230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/58762/prmvend2_conv.mp4?title=TEE+prosthetic+mitral+valve+vegetation\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transophageal echocardiogram (TEE) showing a prosthetic mitral valve vegetation in patient with endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transesophageal echocardiogram shows large vegetations on a prosthetic mitral valve which has limited mobility.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41230=[""].join("\n");
var outline_f40_16_41230=null;
var title_f40_16_41231="Metastatic tuberculous abscesses";
var content_f40_16_41231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metastatic tuberculous abscesses (tuberculous gummas)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple ulcers are present on the back of this patient with metastatic tuberculous abscesses, also known as tuberculous gummas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. M Ramam, New Delhi.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_16_41231=[""].join("\n");
var outline_f40_16_41231=null;
